TY 2010 Form 990

(A) Name and business address	(B) Description of services	(C) Compensation
SCA DIRECT INC 11208 WAPLES MILL RD SUITE 106 FAIRFAX,VA22030	DIRECT MAIL CONSULTING	1,069,573
IMAGE DIRECT 4600 WEDGEWOOD BLVD UNIT N FREDERICK,MD21703	MAILSHOP AND PRINTING	926,173
QUAD GRAPHICS INC 555 SOUTH 108TH STREET WEST ALLIS,WI53214	MAILSHOP AND PRINTING	895,186
BOWERS ENVELOPE CO 5331 N TACOMA AVENUE INDIANAPOLIS,IN46220	PRINTING	711,237
COMMONWEALTH LISTS 11200 WAPLES MILL RD SUITE 150 FAIRFAX,VA22030	LIST RENTAL AND EXCHANGE	570,748
2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 in compensation from the organization 15

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1	Grants and other assistance to governments and organizations in the U.S. See Part IV, line 21	4,899,648	4,899,648
2	Grants and other assistance to individuals in the U.S. See Part IV, line 22
3	Grants and other assistance to governments, organizations, and individuals outside the U.S. See Part IV, lines 15 and 16	694,561	694,561
4	Benefits paid to or for members
5	Compensation of current officers, directors, trustees, and key employees ....	319,443	159,722	95,833	63,888
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) ....
7	Other salaries and wages	1,956,699	899,820	588,845	468,034
8	Pension plan contributions (include section 401(k) and section 403(b) employer contributions) ....	266,749	98,335	88,898	79,516
9	Other employee benefits .......	435,901	155,516	139,198	141,187
10	Payroll taxes ...........	178,352	74,206	58,734	45,412
11	Fees for services (non-employees):
a	Management ......
b	Legal .........	56,722	7,365	49,357
c	Accounting ...........	105,263	37,982	30,112	37,169
d	Lobbying ...........
e	Professional fundraising. See Part IV, line 17..	476,168			476,168
f	Investment management fees ......	105,733		105,733
g	Other ..........	667,225	574,654	45,309	47,262
12	Advertising and promotion ....
13	Office expenses .......	482,964	196,121	181,722	105,121
14	Information technology ......	577,478	305,851	149,711	121,916
15	Royalties ..
16	Occupancy ...........	349,143	162,987	115,009	71,147
17	Travel ............	134,649	81,116	24,529	29,004
18	Payments of travel or entertainment expenses for any federal, state, or local public officials ......
19	Conferences, conventions, and meetings ....	131,981	123,578	3,850	4,553
20	Interest ...........
21	Payments to affiliates .......
22	Depreciation, depletion, and amortization .....	273,219	126,145	86,452	60,622
23	Insurance ..............	53,314	33,527	19,787
24	Other expenses. Itemize expenses not covered above. (Expenses grouped together and labeled miscellaneous may not exceed 5% of total expenses shown on line 25 below.)
a	DIRECT MAIL POSTAGE	3,612,186	2,006,285	192,662	1,413,239
b	DIRECT MAIL PRINT/PUBL.	2,769,601	1,531,828	127,937	1,109,836
c	DIRECT MAIL COMP./MAILS	1,384,179	789,437	73,648	521,094
d	DIRECT MAIL CONSULTING	648,082	590,930	57,152
e	MAILING LIST RENTAL	520,384	263,389	34,588	222,407
f	All other expenses
25	Total functional expenses. Add lines 1 through 24f	21,099,644	13,813,003	2,269,066	5,017,575
26	Joint costs. Check here if following SOP 98-2 (ASC 958-720). Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation	9,394,999	5,181,869	485,987	3,727,143

Part X Balance Sheet
	1	Cashnon-interest-bearing ..........	5,535,237	1	3,151,374
2	Savings and temporary cash investments .......	917,491	2	481,803
3	Pledges and grants receivable, net .........	3,382,454	3	2,575,645
4	Accounts receivable, net .........		4
5	Receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of
	Schedule L ..........		5
6	Receivables from other disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B). Complete Part II of
	Schedule L ..........		6
7	Notes and loans receivable, net .............	388,680	7	316,096
8	Inventories for sale or use ..............	203,848	8	134,231
9	Prepaid expenses and deferred charges ............	169,705	9	90,659
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	11,038,055
b	Less: accumulated depreciation. .....	10b	2,153,265	8,920,355	10c	8,884,790
11	Investments—publicly traded securities ..........	18,646,572	11	18,659,162
12	Investments—other securities. See Part IV, line 11 ......	775,876	12	2,580,114
13	Investments—program-related. See Part IV, line 11 ..		13
14	Intangible assets .........		14
15	Other assets. See Part IV, line 11 ...........	873,158	15	876,256
16	Total assets. Add lines 1 through 15 (must equal line 34)...	39,813,376	16	37,750,130
	17	Accounts payable and accrued expenses .	965,669	17	1,003,163
18	Grants payable ..........	12,513,554	18	11,181,827
19	Deferred revenue ..........		19
20	Tax-exempt bond liabilities ..........	1,560,000	20	1,310,000
21	Escrow or custodial account liability. Complete Part IV of Schedule D..		21
22	Payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........		22
23	Secured mortgages and notes payable to unrelated third parties ..		23
24	Unsecured notes and loans payable to unrelated third parties ....		24
25	Other liabilities. Complete Part X of Schedule D.....	1,611,940	25	1,618,631
26	Total liabilities. Add lines 17 through 25.....	16,651,163	26	15,113,621
		Organizations that follow SFAS 117, check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets .....	9,173,838	27	10,772,583
28	Temporarily restricted net assets .....	13,898,375	28	11,773,926
29	Permanently restricted net assets .....	90,000	29	90,000
	Organizations that do not follow SFAS 117, check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds .....		30
31	Paid-in or capital surplus, or land, building or equipment fund .....		31
32	Retained earnings, endowment, accumulated income, or other funds		32
33	Total net assets or fund balances .....	23,162,213	33	22,636,509
34	Total liabilities and net assets/fund balances .....	39,813,376	34	37,750,130

- TIN:

SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section
4947(a)(1) nonexempt charitable trust.

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization

AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions

The organization is not a private foundation because it is: (For lines 1 through 11, check only one box.)

A church, convention of churches, or association of churches. section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E.)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in

section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in

section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An organization that normally receives: (1) more than 331/3% of its support from contributions, membership fees, and gross

receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of

its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses

acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. Seesection 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box that describes the type of supporting organization and complete lines 11e through 11h.

Type I

Type II

Type III - Functionally integrated

Type III - Other

By checking this box, I certify that the organization is not controlled directly or indirectly by one or more disqualified persons other than foundation managers and other than one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2).

If the organization received a written determination from the IRS that it is a Type I, Type II or Type III supporting organization, check this box ..................................................

Since August 17, 2006, has the organization accepted any gift or contribution from any of the
following persons?

(i) a person who directly or indirectly controls, either alone or together with persons described in (ii)

Yes

and (iii) below, the governing body of the the supported organization? ................

11g(i)

(ii) a family member of a person described in (i) above? ......................

11g(ii)

(iii) a 35% controlled entity of a person described in (i) or (ii) above? ................

11g(iii)

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization in col. (i) listed in your governing document?		(v) Did you notify the organization in col. (i) of your support?		(vi) Is the organization in col. (i) organized in the U.S.?		(vii) Amount of support?
(i) Name of supported organization	(ii) EIN	Yes	No	Yes	No	Yes	No	(vii) Amount of support?


Total

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 11285F

Schedule A (Form 990 or 990-EZ) 2010

Page 2

Part II

Support Schedule for Organizations Described in IRC 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year(or fiscal year beginning in)		(a) 2006	(b) 2007	(c) 2008	(d) 2009	(e) 2010	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") ....	22,632,738	20,785,323	19,950,796	21,879,337	18,261,062	103,509,256
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.......
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3..	22,632,738	20,785,323	19,950,796	21,879,337	18,261,062	103,509,256
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)..
6	Public Support. Subtract line 5 from line 4.						103,509,256

Section B. Total Support

Calendar year(or fiscal year beginning in)		(a) 2006	(b) 2007	(c) 2008	(d) 2009	(e) 2010	(f) Total
7	Amounts from line 4..	22,632,738	20,785,323	19,950,796	21,879,337	18,261,062	103,509,256
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..	1,758,955	1,716,212	1,512,451	1,572,008	1,443,239	8,002,865
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. (Explain in Part IV.) Do not include gain or loss from the sale of capital assets..	9,834	14,798	2,303	1,132	14	28,081
11	Total support (Add lines 7 through 10).						111,540,202

Gross receipts from related activities, etc. (See instructions.) ..................

13,580

First Five Years If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization,
check this box and stop here.......................................... right arrow

Section C. Computation of Public Support Percentage

Public Support Percentage for 2010 (line 6 column (f) divided by line 11 column (f)) .........

92.800 %

Public Support Percentage for 2009 Schedule A, Part II, line 14 ...............

93.160 %

16a

33 1/3% support test—2010. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ...................... right arrow

33 1/3% support test—2009. If the organization did not check the box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2010. If the organization did not check a box on line 13, 16a, or 16b and line 14
is 10% or more, and if the organization meets the "facts and circumstances" test, check this box and stop here. Explain
in Part IV how the organization meets the "facts and circumstances" test. The organization qualifies as a publicly supported
organization .................................................. right arrow

10%-facts-and-circumstances test—2009. If the organization did not check a box on line 13, 16a, 16b, or 17a and line
15 is 10% or more, and if the organization meets the "facts and circumstances" test, check this box and stop here.
Explain in Part IV how the organization meets the "facts and circumstances" test. The organization qualifies as a publicly
supported organization .............................................. right arrow

Private Foundation If the organization did not check a box on line 13, 16a, 16b, 17a or 17b, check this box and see
instructions ................................................... right arrow

Schedule A (Form 990 or 990-EZ) 2010

Page 3

Part III

Support Schedule for Organizations Described in IRC 509(a)(2)
(Complete only if you checked the box on line 9 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year(or fiscal year beginning in)		(a) 2006	(b) 2007	(c) 2008	(d) 2009	(e) 2010	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose......
3	Gross receipts from activities that are not an unrelated trade or business under section 513..
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge..
6	Total. Add lines 1 through 5.
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons...
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public Support (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2006	(b) 2007	(c) 2008	(d) 2009	(e) 2010	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.)
13	Total support (Add lines 9, 10c, 11 and 12.).

Section C. Computation of Public Support Percentage

Public Support Percentage for 2010 (line 8 column (f) divided by line 13 column (f)) .........

Public support percentage from 2009 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2010 (line 10c column (f) divided by line 13 column (f)) ......

Investment income percentage from 2009 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests—2010. If the organization did not check the box on line 14, and line 15 is more than 33 1/3% and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization .......... right arrow

33 1/3% support tests—2009. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization .... right arrow

Private Foundation If the organization did not check a box on line 14, 19a or 19b, check this box and see instructions ..... right arrow

Schedule A (Form 990 or 990-EZ) 2010

Page 4

Part IV

Supplemental Information. Supplemental Information. Complete this part to provide the explanation required by Part II, line 10; Part II, line 17a or 17b; or Part III, line 12. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Explanation

Schedule A (Form 990 or 990-EZ) 2010

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990, 990-EZ,
or 990-PF)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

OMB No. 1545-0047

2010

Name of organization

AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note. Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, $5,000 or more (in money or
property) from any one contributor. Complete Parts I and II.

Special Rules

For a section 501(c)(3) organization filing Form 990 or 990-EZ, that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi), and received from any one contributor, during the year, a contribution of the
greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For a section 501(c)(7), (8), or (10) organization filing Form 990, or 990-EZ, that received from any one contributor,
during the year, aggregate contributions of more than $1,000 for use exclusively for religious, charitable,
scientific, literary, or educational purposes, or the prevention of cruelty to children or animals. Complete Parts I, II, and
III.

For a section 501(c)(7), (8), or (10) organization filing Form 990, or 990-EZ, that received from any one contributor,
during the year, contributions for use exclusively for religious, charitable, etc., purposes, but these contributions did
not aggregate to more than $1,000. If this box is checked, enter here the total contributions that were received during
the year for an exclusively religious, charitable, etc., purpose. Do not complete any of the parts unless the General Rule
applies to this organization because it received nonexclusively religious, charitable, etc., contributions of $5,000 or more
during the year. ......................... Arrow Bullet

Caution. An Organization that is not covered by the General Rule and/or the Special Rules does not file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2 of its Form 990, or check the box in the heading of its
Form 990-EZ, or on line 2 of its Form 990-PF, to certify that it does not meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990, 990-EZ, or 990-PF) (2010)

Name of organization AMERICAN HEALTH ASSISTANCE FOUNDATION
Schedule B (Form 990, 990-EZ, or 990-PF) (2010) Page 1 of 1 of Part I
Part I	Contributors (see Instructions)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
RESTRICTED	RESTRICTED RESTRICTED RESTRICTED RESTRICTED, RESTRICTED RESTRICTED	$RESTRICTED	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Aggregate contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
Schedule B (Form 990, 990-EZ, or 990-PF) (2010)

Name of organization AMERICAN HEALTH ASSISTANCE FOUNDATION
Schedule B (Form 990, 990-EZ, or 990-PF) (2010) Page 1 of 1 of Part II
Part II	Noncash Property (see Instructions)
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
Schedule B (Form 990, 990-EZ, or 990-PF) (2010)

Schedule B (Form 990, 990-EZ, or 990-PF) (2010)

Page 1 of 1 of Part III

Name of organization
AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Part III

Exclusively religious, charitable, etc., individual contributions to section 501(c)(7), (8), or (10) organizations
aggregating more than $1,000 for the year. (Complete columns (a) through (e) and the following line entry.)
For organizations completing Part III, enter the total of exclusively religious, charitable, etc.,
contributions of $1,000 or less for the year. (Enter this information once. See instructions.) Arrow Bullet

(a) No.
from
Part I

(b)
Purpose of gift

(d)
Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b)
Purpose of gift

(d)
Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b)
Purpose of gift

(d)
Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b)
Purpose of gift

(d)
Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990, 990-EZ, or 990-PF) (2010)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," to Form 990,
Part IV, line 6, 7, 8, 9, 10, 11, or 12.
SchDMd Bullet

Attach to Form 990. SchDMd Bullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization

AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" to Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .......
2	Aggregate contributions to (during year) ...
3	Aggregate grants from (during year) ...
4	Aggregate value at end of year .......

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised
funds are the organization's property, subject to the organization's exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds may be
used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit. ...................................

Yes No

Part II

Conservation Easements. Complete if the organization answered "Yes" to Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or pleasure) Preservation of an historically importantly land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a–2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements .......................	2a
b	Total acreage restricted by conservation easements ..................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 8/17/06 ........	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during
the taxable year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and
enforcement of the conservation easements it holds? .............................

Yes No

Staff and volunteer hours devoted to monitoring, inspecting and enforcing conservation easements during the year SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, and enforcing conservation easements during the year SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section
170(h)(4)(B)(i) and 170(h)(4)(B)(ii)? ....................................

Yes No

In Part XIV, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" to Form 990, Part IV, line 8.

If the organization elected, as permitted under SFAS 116, not to report in its revenue statement and balance sheet works of
art, historical treasures, or other similar assets held for public exhibition, education or research in furtherance of public service,
provide, in Part XIV, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under SFAS 116, to report in its revenue statement and balance sheet works of art,
historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service,
provide the following amounts relating to these items:

(i)

Revenues included in Form 990, Part VIII, line 1 ........................ SchDMd Bullet

(ii)

Assets included in Form 990, Part X .............................. SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under SFAS 116 relating to these items:

Revenues included in Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Privacy Act and Paperwork Reduction Act Notice, see the Intructions for Form 990

Cat. No. 52283D

Schedule D (Form 990) 2010

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s accession and other records, check any of the following that are a significant use of its collection
items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIV.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?........

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" to Form 990,
Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No

If "Yes," explain the arrangement in Part XIV and complete the following table:


c	Beginning balance .................................	1c
d	Additions during the year ..............................	1d
e	Distributions during the year .............................	1e
f	Ending balance ...................................	1f

Did the organization include an amount on Form 990, Part X, line 21? .....................

Yes No

If “Yes,” explain the arrangement in Part XIV.

Part V

Endowment Funds. Complete if the organization answered "Yes" to Form 990, Part IV, line 10.

		(a)Current Year	(b)Prior Year	(c)Two Years Back
1a	Beginning of year balance ....	90,000	90,000	90,000
b	Contributions ........	3,792	3,715	4,009
c	Investment earnings or losses ...
d	Grants or scholarships .....
e	Other expenditures for facilities and programs ........	3,792	3,715	4,009
f	Administrative expenses ....
g	End of year balance ......	90,000	90,000	90,000

Provide the estimated percentage of the year end balance held as:

Board designated or quasi-endowment: SchDMd Bullet

Permanent endowment: SchDMd Bullet

100.000 %

Term endowment: SchDMd Bullet

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) unrelated organizations ........................

3a(i)

(ii) related organizations ........................

3a(ii)

If "Yes" to 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIV the intended uses of the organization's endowment funds.

Part VI

InvestmentsLand, Buildings, and Equipment. See Form 990, Part X, line 10.

Description of investment		(a) Cost or other basis (investment)	(b)Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a	Land .................	2,800,000	1,147,363		3,947,363
b	Buildings ................	1,629,400	4,533,166	1,499,691	4,662,875
c	Leasehold improvements ............
d	Equipment ................		733,854	475,825	258,029
e	Other .................		194,272	177,749	16,523
Total. Add lines 1a-1e. (Column (d) should equal Form 990, Part X, column (B), line 10(c).)........					8,884,790

Schedule D (Form 990) 2010

Page 3

Part VII

InvestmentsOther Securities. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b)Book value	(c) Method of valuation: Cost or end-of-year market value
(1)Financial derivatives
(2)Closely-held equity interests
(3)Other (A) ALTERNATIVE INVESTMENTS - PARTNERSHIP	849,950	F
(B) CHARITABLE LEAD AND REMAINDER TRUSTS	1,640,164	F
(C) PERPETUAL TRUST	90,000	F






Total. (Column (b) should equal Form 990, Part X, col.(B) line 12.)	2,580,114

Part VIII

InvestmentsProgram Related. See Form 990, Part X, line 13.

(a) Description of investment type		(b) Book value	(c) Method of valuation: Cost or end-of-year market value









Total. (Column (b) should equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets. See Form 990, Part X, line 15.

(a) Description				(b) Book value









Total. (Column (b) should equal Form 990, Part X, col.(B) line 15.)...........

Part X

Other Liabilities. See Form 990, Part X, line 25.

1.(a) Description of Liability		(b) Amount
Federal Income Taxes
CHARITABLE GIFT ANNUITIES		1,443,362
RENTAL DEPOSITS		25,000
INTEREST RATE SWAP LIABILITY		21,806
CAPITAL LEASE OBLIGATIONS		128,463





Total. (Column (b) should equal Form 990, Part X, col.(B) line 25.)		1,618,631
2. Fin 48 (ASC 740) Footnote. In Part XIV, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC740).

Schedule D (Form 990) 2010

Page 4

Part XI Reconciliation of Change in Net Assets from Form 990 to Financial Statements
1	Total revenue (Form 990, Part VIII, column (A), line 12) ....................	1	21,542,964
2	Total expenses (Form 990, Part IX, column (A), line 25) .....................	2	21,099,644
3	Excess or (deficit) for the year. Subtract line 2 from line 1 .............	3	443,320
4	Net unrealized gains (losses) on investments ..........................	4	-1,015,819
5	Donated services and use of facilities .............................	5
6	Investment expenses ...................................	6
7	Prior period adjustments ..................................	7
8	Other (Describe in Part XIV) .................................	8	46,795
9	Total adjustments (net). Add lines 4 - 8 .............................	9	-969,024
10	Excess or (deficit) for the year per financial statements. Combine lines 3 and 9 .........	10	-525,704

Part XII Reconciliation of Revenue per Audited Financial Statements With Revenue per Return
1	Total revenue, gains, and other support per audited financial statements .......			1	40,082,707
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains on investments ..........	2a	-1,015,819
b	Donated services and use of facilities .........	2b	19,538,608
c	Recoveries of prior year grants ...........	2c	80,908
d	Other (Describe in Part XIV): ............	2d
e	Add lines 2a through 2d .....................			2e	18,603,697
3	Subtract line 2e from line 1.....................			3	21,479,010
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a	105,733
b	Other (Describe in Part XIV): ...........	4b	-41,779
c	Add lines 4a and 4b.......................			4c	63,954
5	Total Revenue. Add lines 3 and 4c. (This should equal Form 990, Part I, line 12.) ......			5	21,542,964

Part XIII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return
1	Total expenses and losses per audited financial statements .............			1	40,608,411
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities ..........	2a	19,538,608
b	Prior year adjustments ..............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIV): ............	2d	34,113
e	Add lines 2a through 2d......................			2e	19,572,721
3	Subtract line 2e from line 1.....................			3	21,035,690
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a	105,733
b	Other (Describe in Part XIV): ............	4b	-41,779
c	Add lines 4a and 4b.......................			4c	63,954
5	Total expenses. Add lines 3 and 4c. (This should equal Form 990, Part I, line 18.) ......			5	21,099,644

Part XIV

Supplemental Information

Complete this part to provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b;
Part V, line 4; Part X; Part XI, line 8; Part XII, lines 2d and 4b; and Part XIII, lines 2d and 4b. Also complete this part to provide any additional information.

Identifier	Return Reference	Explanation
DESCRIPTION OF INTENDED USE OF ENDOWMENT FUNDS:	PART V, LINE 4:	THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR ALZHEIMER'S DISEASE RESEARCH AND ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT INCOME AND RELEASED AS SPENT.
DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48:	PART X:	AHAF HAS ADOPTED THE GUIDANCE UNDER ASC TOPIC INCOME TAXES RELATED TO ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. MANAGEMENT OF AHAF BELIEVES THAT AHAF HAS NO MATERIAL UNCERTAIN TAX POSITIONS AND, ACCORDINGLY, IT WILL NOT RECOGNIZE ANY LIABILITY FOR UNRECOGNIZED TAXES.
PART XI, LINE 8 - OTHER ADJUSTMENTS:		RECOVERIES OF PRIOR YEAR GRANTS 80,908. CHANGE IN PRESENT VALUE OF GRANTS -8,922. SPECIAL EVENT NET INCOME -25,191.
PART XII, LINE 4B - OTHER ADJUSTMENTS:		DEPRECIATION ON RENTAL PROPERTY -41,779.
PART XIII, LINE 2D - OTHER ADJUSTMENTS:		CHANGE IN PRESENT VALUE OF GRANTS 8,922. SPECIAL EVENT NET INCOME 25,191.
PART XIII, LINE 4B - OTHER ADJUSTMENTS:		DEPRECIATION ON RENTAL PROPERTY -41,779.

Schedule D (Form 990) 2010

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE F
(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990,
Part IV, line 14b, 15, or 16.
Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization
AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Part I

General Information on Activities Outside the United States. Complete if the organization answered
“Yes” to Form 990, Part IV, line 14b.

For grantmakers. Does the organization maintain records to substantiate the amount of the grants or

assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award

the grants or assistance? ...................................

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of grant funds outside the
United States.

Activites per Region. (Use Part V if additional space is needed.)

(a) Region		(c) Number of employees or agents in region or independent contractors	(d) Activities conducted in region (by type) (e.g., fundraising, program services, investments, grants to recipients located in the region)	(f) Total expenditures for region/investments in region
	EUROPE (INCLUDING ICELAND & GREENLAND)		GRANTMAKING	500,000
	EAST ASIA AND THE PACIFIC		GRANTMAKING	194,561















3a	Sub-total .....	0		694,561
b	Total from continuation sheets to Part I ...	0		0
c	Totals (add lines 3a and 3b)	0		694,561

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2010

Schedule F (Form 990) 2010

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" to Form 990,

Part IV, line 15, for any recipient who received more than $5,000. Check this box if no one recipient received more than $5,000 ........ MediumBullet

Use Part V if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement
EUROPE (INCLUDING ICELAND & GREENLAND)	NATIONAL GLAUCOMA RESEARCH BY DR. JULIE ALBON ENTITLED: (G2011006)	100,000	WIRE TRANSFER
EAST ASIA AND THE PACIFIC	NATIONAL GLAUCOMA RESEARCH BY DR. C. KAI-SHUN LEUNG ENTITLED: (G2011007)	100,000	WIRE TRANSFER
EUROPE (INCLUDING ICELAND & GREENLAND)	NATIONAL GLAUCOMA RESEARCH BY DR. DARRYL RAY OVERBY ENTITLED: (G2011020)	100,000	WIRE TRANSFER
EUROPE (INCLUDING ICELAND & GREENLAND)	NATIONAL GLAUCOMA RESEARCH BY DR. MICHAEL J. A. GIRARD ENTITLED: (G2011019)	100,000	WIRE TRANSFER
EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE REASEARCH BY DR. MICHAEL ROHE ENTITLED: (A2011601)	100,000	WIRE TRANSFER
EAST ASIA AND THE PACIFIC	MACULAR DEGENERATION RESEARCH BY DR. TIEN YIN WONG ENTITLED: (M2011068)	94,561	WIRE TRANSFER
EUROPE (INCLUDING ICELAND & GREENLAND)	MACULAR DEGENERATION RESEARCH BY DR. PETER HUMPHRIES ENTITLED: (M2011034)	100,000	WIRE TRANSFER

Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter ..... MediumBullet

Enter total number of other organizations or entities ........................ MediumBullet

Schedule F (Form 990) 2010

Schedule F (Form 990) 2010Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 16.

Use Part V if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of non-cash assistance	(g) Description of non-cash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2010

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2010

Page 5

Part V

Supplemental Information
Complete this part to provide the information (see instructions) required in Part I, line 2, and any additional information.

Identifier	ReturnReference	Explanation
PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.:		SCHEDULE F, PART I, LINE 2: AHAF INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO AHAF. THESE ARE RECEIVED BY THE AHAF SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE IN MOLECULAR BIOLOGY, CELL BIOLOGY, BIOCHEMISTRY, IMAGING AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATE THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE AHAF SCIENTIFIC REVIEW COMMITTEES WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH AHAF SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, THE AHAF STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE BOARD OF DIRECTORS GRANTS COMMITTEE. THE SCIENTIFIC AFFAIRS SENIOR STAFF IS EMPOWERED TO AUTHORIZE THE WITHHOLDING OF FUNDING, OR DISCONTINUATIONS OF AWARDS, FOR ANY GRANTEES THAT FAIL TO ACHIEVE SUFFICIENT PROGRESS OR FAIL TO SUBMIT REQUIRED REPORTS. AT THE CONCLUSION OF THE GRANT AWARD PERIOD EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE AHAF SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF AHAF SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY AHAF. THIS IMPACT IS FURTHER SUPPORTED BY THE 2010 PUBLICATION CITATION ANALYSIS THAT COMPARED 1789 AHAF SUPPORTED WORKS TO 3996 WORKS SUPPORTED BY EITHER THE US FEDERAL GOVERNMENT OR THAT OF OTHER FUNDING AGENCIES. AHAF SUPPORTED PUBLICATIONS WERE CITED NEARLY TWICE AS FREQUENTLY AS THE SAMPLE OF PAPERS PUBLISHED UNDER THE SOLE SPONSORSHIP OF THE US GOVERNMENT. WITH RESPECT TO A SELECTION OF MANUSCRIPTS THAT LISTED SOLELY NON-US GOVERNMENT FUNDING SOURCES, INCLUDING OTHER FOUNDATIONS, INDUSTRY, AND FOREIGN GOVERNMENTS, AHAF SPONSORED PUBLICATIONS WERE CITED, ON AVERAGE 2.3 TIMES MORE FREQUENTLY THAN THE OTHER FUNDING SOURCES. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF AHAF GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES 2.2 ADDITIONAL GRANTS FOR PROJECTS SPAWNED BY THE AHAF GRANT. THESE COME AT VALUES NEARLY 10 TIMES THE LEVEL OF THE INITIAL AHAF INVESTMENT. AHAF SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THE FINAL REPORT PACKAGE INCLUDES A PAGE TO BE DETACHED AND ANONYMOUSLY MAILED TO THE SCIENTIFIC AFFAIRS DEPARTMENT. THIS DOCUMENT REQUESTS AN ASSESSMENT OF THE GRANTEE EXPERIENCE AS AN AHAF AWARDEE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF AHAF ON THIS FORM SO THAT AHAF CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR SCIENTIFIC STAFF PRESENT AND SUMMARIZE THE STATUS AND PROGRESS ON ALL GRANTS TO THE AHAF BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

Schedule F (Form 990) 2010

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE G
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding
Fundraising or Gaming Activities

Complete if the organization answered "Yes" to Form 990, Part IV, lines 17, 18, or 19,
or if the organization entered more than $15,000 on Form 990-EZ, line 6a.
right arrow

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization
AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Part I

Fundraising Activities. Complete if the organization answered "Yes" to Form 990, Part IV, line 17.

Indicate whether the organization raised funds through any of the following activities. Check all that apply.

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and e-mail solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations

Did the organization have a written or oral agreement with any individual (including officers, directors, trustees

or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

Yes

If “Yes,” list the ten highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization. Form 990-EZ filers are not required to complete this table.

(i) Name and address of individual or entity (fundraiser)	(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
	(ii) Activity	Yes	No	(iv) Gross receipts from activity		(vi) Amount paid to (or retained by) organization
SCA DIRECT INC 11200 WAPLES MILL ROAD SUITE 150 FAIRFAX, VA22030	DIRECT MAIL FUND. COUNSEL		No	13,483,287	1,050,000	12,433,287
THE SHARPE GROUP 8700 TRAIL LAKE DRIVE WEST SUITE 2 MEMPHIS, TN38125	PLANNED GIVING CONSULTING		No	1,460,789	15,600	1,445,189
Total .................				14,944,076	1,065,600	13,878,476

List all states in which the organization is registered or licensed to solicit funds or has been notified it is exempt from registration or licensing.

AL, AK, AZ, AR, CA, CO, CT, DC, FL, GA, HI, IL, KS, KY, LA, ME, MD, MA, MH, MI, MN, MS, MO, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WV, WI

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50083H

Schedule G (Form 990 or 990-EZ) 2010

Page 2

Part II

Fundraising Events. Complete if the organization answered "Yes" to Form 990, Part IV, line 18, or reported more than $15,000 on Form 990-EZ, line 6a. List events with gross receipts greater than $5,000.

		(a) Event #1 GOLF TOURNAMENT (event type)	(d) Total Events (Add col. (a) through col. (c))
1	Gross receipts . . .	54,222	54,222
2	Less: Charitable contributions . . .	40,642	40,642
3	Gross income (line 1 minus line 2) . . .	13,580	13,580
4	Cash prizes . . .	455	455
5	Non-cash prizes . .	4,933	4,933
6	Rent/facility costs . .	10,763	10,763
7	Food and beverages . .	5,372	5,372
8	Entertainment . . .
9	Other direct expenses .	17,248	17,248
10	Direct expense summary. Add lines 4 through 9 in column (d) ...........		38,771
11	Net income summary. Combine lines 3 and 10 in column (d)............		-25,191

Part III

Gaming. Complete if the organization answered "Yes" to Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

(a) Bingo

(b) Pull tabs/Instant
bingo/progressive bingo

(c) Other gaming

(d) Total gaming (Add col. (a) through col. (c))

Gross revenue . . . .

Cash prizes . . . .

Non-cash prizes . . .

Rent/facility costs . . .

Other direct expenses . .

Volunteer labor . . .

	Yes
	No

	Yes
	No

	Yes
	No

Direct expense summary. Add lines 2 through 5 in column (d) ........... right arrow

Net gaming income summary. Combine lines 1 and 7 in column (d) .......... right arrow

Enter the state(s) in which the organization operates gaming activities:

Is the organization licensed to operate gaming activities in each of these states? ............

YesNo

If "No," Explain:

10a

Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? .....

YesNo

If "Yes," Explain:

Does the organization operate gaming activities with nonmembers? .................

YesNo

Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity

formed to administer charitable gaming? ...........................

YesNo

Schedule G (Form 990 or 990-EZ) 2010

Page 3

Indicate the percentage of gaming activity operated in:

The organization's facility ......................

13a

An outside facility ........................

13b

Provide the name and address of the person who prepares the organization's gaming/special events books and records:

Name

Address

15a

Does the organization have a contract with a third party from whom the organization receives gaming

revenue? ......................................

YesNo

If "Yes," enter the amount of gaming revenue received by the organization right arrow

$ and the

amount of gaming revenue retained by the third party right arrow

$ .

If "Yes," enter name and address:

Name

Address

Gaming manager information:

Name

Gaming manager compensation right arrow

Description of services provided right arrow

Director/officer Employee Independent contractor

Mandatory distributions:

Is the organization required under state law to make charitable distributions from the gaming proceeds to

retain the state gaming license? ............................

YesNo

Enter the amount of distributions required under state law distributed to other exempt organizations or spent

in the organization's own exempt activities during the tax year right arrow

Part IV

Complete this part to provide additional information for responses to quuestion on Schedule G (see instructions.)

Identifier	ReturnReference	Explanation
EXPLANATION OF FUNDRAISING PAYMENTS	SCHEDULE G, PART I, LINE 2B, COLUMN (V)	IN THE CONTRACT WITH SCA DIRECT, INC., THE MANAGEMENT FEE IS A FIXED AMOUNT PER MONTH FOR IN SCOPE SERVICES. WORK PERFORMED OUT OF THE SCOPE OF FUNDRAISING SERVICES ARE APPROVED BY AHAF BEFORE THEY ARE PAID AND PERFORMED. THE SHARPE GROUPE PROVIDED AHAF WITH ADVICE ON PLANNED GIVING MATTERS.

Schedule G (Form 990 or 990-EZ) 2010

Additional Data

Software ID:
Software Version:

- TIN:

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," to Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization
AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number
23-7337229

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ....................................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Governments and Organizations in the United States. Complete if the organization answered "Yes" to
Form 990, Part IV, line 21 for any recipient that received more than $5,000. Check this box if no one recipient received more than $5,000. Use
Part IV and Schedule I-1 (Form 990) if additional space is needed ......................... lBullet

(a) Name and address of organization or government	(b) EIN	(c) IRC Code section if applicable	(d) Amount of cash grant	(h) Purpose of grant or assistance
(1) UNIVERSITY OF PENNSYLVANIA3451 WALNUT STREET P221 PHILADELPHIA,PA191046205	23-1352685	501(C)(3)	250,000	ALZHEIMER'S DISEASE REASEARCH BY DR. PAUL H. AXELSEN ENTITLED: (A2011044)
(2) UNIVERSITY OF MIAMI1501 NW 10TH AVENUE ROOM 314 MIAMI,FL33136	59-0624458	501(C)(3)	400,000	ALZHEIMER'S DISEASE REASEARCH BY DR. MARGARET A. PERICAK-VANCE ENTITLED: (A2011048)
(3) UNIVERSITY OF CHICAGO5801 SOUTH ELLIS AVENUE CHICAGO,IL60637	36-2177139	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY DR. SANGRAM S. SISODIA ENTITLED: (A2011054)
(4) MEDICAL UNIVERSITY OF SOUTH CAROLINA171 ASHLEY AVENUE CHARLESTON,MA29425	57-6000722	501(C)(3)	399,873	ALZHEIMER'S DISEASE REASEARCH BY DR. NARAYAN R. BHAT ENTITLED: (A2011081)
(5) MAYO CLINIC200 FIRST STREET SW ROCHESTER,NY55905	41-6011702	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY DR. EUGENIA TRUSHINA ENTITLED: (A2011084)
(6) MASSACHUSETTS GENERAL HOSPITAL55 FRUIT STREET BOSTON,MA021142696	07-3130411	501(C)(3)	399,939	ALZHEIMER'S DISEASE REASEARCH BY DR. BRADLEY T. HYMAN ENTITLED: (A2011086)
(7) CASE WESTERN RESERVE UNIVERSITY10900 EUCLID AVENUE CLEVELAND,OH441064919	34-1018992	501(C)(3)	250,000	ALZHEIMER'S DISEASE REASEARCH BY DR. GARY E. LANDRETH ENTITLED: (A2011102)
(8) UNIVERSITY OF PENNSYLVANIA3451 WALNUT STREET/P221 PHILADELPHIA,PA191046205	23-1352685	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY DR. KURT R. BRUNDEN ENTITLED: (A2011303)
(9) ROCKEFELLER UNIVERSITY1230 YORK AVENUE NEW YORK,NY10065	13-1624158	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY DR. MARTA CORTES-CANTELI ENTITLED: (A2011310)
(10) RESEARCH FOUNDATION FOR MENTAL HYGIENE INC AT IBR150 BROADWAY SUITE 301 MENANDS,NY12204	14-1410842	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY DR. MASUO OHNO ENTITLED: (A2011311)
(11) RENSSELAER POLYTECHNIC INSTITUTE110 EIGHTH STREET TROY,NY12180	14-1340095	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY DR. PETER MATTHEW TESSIER ENTITLED: (A2011355)
(12) NORTHWESTERN UNIVERSITY2029 SHERIDAN ROAD EVANSTON,IL602082710	36-2167817	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY KEN A. PALLER, PH. D. ENTITLED: (A2011362)
(13) MEDICAL COLLEGE OF WISCONSIN8701 WATERTOWN PLANK ROAD MILWAUKEE,WI53226	39-0806261	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY DR. NASHAAT Z. GERGES ENTITLED: (A2011367)
(14) MAYO CLINIC4500 SAN PABLO ROAD SOUTH JACKSONVILLE,FL32224	59-3337028	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY DR. MICHAEL ANTHONY DETURE ENTITLED: (A2011368)
(15) LERNER RESEARCH INSTITUTE CLEVELAND CLINIC FOUNDATIONNC 30 9500 EUCLID AVENUE CLEVELAND,OH44195	34-0714585	501(C)(3)	150,000	ALZHEIMER'S DISEASE REASEARCH BY DR. KIRAN BHASKAR ENTITLED: (A2011372)
(16) THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO7703 FLOYD CURL DRIVE SAN ANTONIO,TX70229	74-1586031	501(C)(3)	100,000	ALZHEIMER'S DISEASE REASEARCH BY DR. BIJU K. CHANDU ENTITLED: (A2011615)
(17) INDIANA UNIVERSITY620 UNION DRIVE INDIANAPOLIS,IN462025167	35-6001673	501(C)(3)	100,000	NATIONAL GLAUCOMA RESEARCH BY DR. BRIAN CHRISTOPHER SAMUELS ENTITLED: (G2011012)
(18) UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTERCBH440 3500 CAMP BOWIE BOULEVARD FORT WORTH,TX76107	75-6064033	501(C)(3)	100,000	NATIONAL GLAUCOMA RESEARCH BY DR. WEIMING MAO ENTITLED: (G2011032)
(19) NORTHWESTERN UNIVERSITY633 CLARK STREET EVANSTON,IL60208	36-2167817	501(C)(3)	100,000	NATIONAL GLAUCOMA RESEARCH BY DR. XIAORONG LIU ENTITLED: (G2011033)
(20) RUSH UNIVERSITY MEDICAL CENTER1735 W HARRISON STREET 318 CHICAGO,IL60612	36-2174823	501(C)(3)	100,000	NATIONAL GLAUCOMA RESEARCH BY DR. SHUNBIN XU ENTITLED: (G2011036)
(21) UNIVERSITY OF ILLINOIS AT CHICAGO1885 W TAYLOR STREET CHICAGO,IL60302	37-6000511	501(C)(3)	100,000	NATIONAL GLAUCOMA RESEARCH BY PAUL A. KNEPPER ENTITLED: (G2011047)
(22) VANDERBILT UNIVERSITY MEDICAL CENTER11435 MRB IV 2215B GARLAND AVENUE NASHVILLE,TN37232	62-0476822	501(C)(3)	100,000	NATIONAL GLAUCOMA RESEARCH BY DR. DAVID JOHN CALKINS ENTITLED: (G2011052)
(23) WASHINGTON UNIVERSITY660 SOUTH EUCLID AVENUE ST LOUIS,MO63110	43-0653611	501(C)(3)	100,000	MACULAR DEGENERATION RESEARCH BY DR. THOMAS A. FERGUSON ENTITLED: (M2011014)
(24) UNIVERSITY OF FLORIDA219 GRINTER HALL GAINESVILLE,FL32611	59-6002052	501(C)(3)	100,000	MACULAR DEGENERATION RESEARCH BY DR. MICHAEL E. BOULTON ENTITLED: (M2011017)
(25) UNIVERSITY OF IOWA6-430 BOWEN SCIENCE BUILDING IOWA CITY,IA52242	42-6004813	501(C)(3)	100,000	MACULAR DEGENERATION RESEARCH BY DR. VINIT B. MAHAJAN ENTITLED: (M2011021)
(26) VANDERBILT UNIVERSITY MEDICAL CENTER11435 MRB IV 2215B GARLAND AVENUE NASHVILLE,TN37232	62-0476822	501(C)(3)	100,000	MACULAR DEGENERATION RESEARCH BY DR. JONATHAN L. HAINES ENTITLED: (M2011046)
(27) UNIVERSITY OF PENNSYLVANIA3451 WALNUT STREET P221 PHILADELPHIA,PA191046205	23-1352685	501(C)(3)	100,000	MACULAR DEGENERATION RESEARCH BY DR. WENCHAO SONG ENTITLED: (M2011051)
(28) UNIVERSITY OF NOTRE DAME940 GRACE HALL NOTRE DAME,IN46556	35-0868188	501(C)(3)	100,000	MACULAR DEGENERATION RESEARCH BY DR. DAVID RUSSELL HYDE ENTITLED: (M2011053)
(29) UNIVERSITY OF CALIFORNIA3227 CHEADLE HALL SANTA BARBARA,CA931062050	95-6006145	501(C)(3)	100,000	MACULAR DEGENERATION RESEARCH BY DR. MONTE JOEL RADEKE ENTITLED: (M2011064)
(30) THE SCHEPENS EYE RESEARCH INSTITUTE20 STAINFORD STREET BOSTON,MA02114	04-2129889	501(C)(3)	99,836	MACULAR DEGENERATION RESEARCH BY DR. BRUCE RICHARD KSANDER ENTITLED: (M2011069)
(31) JOHNS HOPKINS UNIVERSITY733 N BROADWAY SUITE 117 BALTIMORE,MD21205	52-0595110	501(C)(3)	100,000	MACULAR DEGENERATION RESEARCH BY DR. DONALD J. ZACK ENTITLED: (M2011077)
(32) UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE1501 NW 10TH AVENUE ROOM 314 MIAMI,FL33136	59-0624458	501(C)(3)	100,000	MACULAR DEGENERATION RESEARCH BY DR. MARGARET A. PERICAK-VANCE ENTITLED: (M2011078)

Enter total number of section 501(c)(3) and government organizations ......................... Bullet Image

Enter total number of other organizations ................................ . Bullet Image

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2010

Page 2

Part III

Grants and Other Assistance to Individuals in the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 22.
Use Schedule I-1 (Form 990) if additional space is needed.

(a)Type of grant or assistance	(b)Number of recipients	(c)Amount of cash grant	(d)Amount of non-cash assistance	(e)Method of valuation (book, FMV, appraisal, other)	(f)Description of non-cash assistance

Part IV

Supplemental Information. Complete this part to provide the information required in Part I, line 2, and any other additional information.

Identifier	Return Reference	Explanation
PROCEDURE FOR MONITORING GRANTS IN THE U.S.:	PART I, LINE 2:	SCHEDULE I, PART I, LINE 2: AHAF INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO AHAF. THESE ARE RECEIVED BY THE AHAF SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE IN MOLECULAR BIOLOGY, CELL BIOLOGY, BIOCHEMISTRY, IMAGING AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATE THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE AHAF SCIENTIFIC REVIEW COMMITTEES WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH AHAF SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, THE AHAF STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE BOARD OF DIRECTORS GRANTS COMMITTEE. THE SCIENTIFIC AFFAIRS SENIOR STAFF IS EMPOWERED TO AUTHORIZE THE WITHHOLDING OF FUNDING, OR DISCONTINUATIONS OF AWARDS, FOR ANY GRANTEES THAT FAIL TO ACHIEVE SUFFICIENT PROGRESS OR FAIL TO SUBMIT REQUIRED REPORTS. AT THE CONCLUSION OF THE GRANT AWARD PERIOD EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE AHAF SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF AHAF SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY AHAF. THIS IMPACT IS FURTHER SUPPORTED BY THE 2010 PUBLICATION CITATION ANALYSIS THAT COMPARED 1789 AHAF SUPPORTED WORKS TO 3996 WORKS SUPPORTED BY EITHER THE US FEDERAL GOVERNMENT OR THAT OF OTHER FUNDING AGENCIES. AHAF SUPPORTED PUBLICATIONS WERE CITED NEARLY TWICE AS FREQUENTLY AS THE SAMPLE OF PAPERS PUBLISHED UNDER THE SOLE SPONSORSHIP OF THE US GOVERNMENT. WITH RESPECT TO A SELECTION OF MANUSCRIPTS THAT LISTED SOLELY NON-US GOVERNMENT FUNDING SOURCES, INCLUDING OTHER FOUNDATIONS, INDUSTRY, AND FOREIGN GOVERNMENTS, AHAF SPONSORED PUBLICATIONS WERE CITED, ON AVERAGE 2.3 TIMES MORE FREQUENTLY THAN THE OTHER FUNDING SOURCES. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF AHAF GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES 2.2 ADDITIONAL GRANTS FOR PROJECTS SPAWNED BY THE AHAF GRANT. THESE COME AT VALUES NEARLY 10 TIMES THE LEVEL OF THE INITIAL AHAF INVESTMENT. AHAF SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THE FINAL REPORT PACKAGE INCLUDES A PAGE TO BE DETACHED AND ANONYMOUSLY MAILED TO THE SCIENTIFIC AFFAIRS DEPARTMENT. THIS DOCUMENT REQUESTS AN ASSESSMENT OF THE GRANTEE EXPERIENCE AS AN AHAF AWARDEE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF AHAF ON THIS FORM SO THAT AHAF CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR SCIENTIFIC STAFF PRESENT AND SUMMARIZE THE STATUS AND PROGRESS ON ALL GRANTS TO THE AHAF BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

Schedule I (Form 990) 2010

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" to Form 990,
Part IV, question 23.
SchJMediumBullet

Attach to Form 990. SchJMediumBullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization

AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed in Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes in line 1a are checked, did the organization follow a written policy regarding payment or reimbursement orprovision of all the expenses described above? If "No," complete Part III to explain....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
officers, directors, trustees, and the CEO/Executive Director, regarding the items checked in line 1a? ....

Indicate which, if any, of the following the organization uses to establish the compensation of the
organization's CEO/Executive Director. Check all that apply.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed in Form 990, Part VII, Section A, line 1a with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? ...............

Participate in, or receive payment from, a supplemental nonqualified retirement plan? ........

Participate in, or receive payment from, an equity-based compensation arrangement? ........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3) and 501(c)(4) organizations only must complete lines 5-9.

For persons listed in form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 5a or 5b, describe in Part III.

For persons listed in form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 6a or 6b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization provide any non-fixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Were any amounts reported in Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regs. section 53.4958-4(a)(3)? If "Yes," describe
in Part III .............................

If "Yes" to line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Privacy Act and Paperwork Reduction Act Notice, see the Intructions for Form 990

Cat. No. 50053T

Schedule J (Form 990) 2010

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use Schedule J-1 if additional space needed.

For each individual whose compensation must be reported in Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.

Note. The sum of columns (B)(i)-(iii) must equal the applicable column (D) or column (E) amounts on Form 990, Part VII, line 1a.

(A) Name		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported in prior Form 990 or Form 990-EZ
(A) Name		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
(1) STACY PAGOS HALLER	(i) (ii)	244,752 0	0 0	552 0	0 0	29,869 0	275,173 0	0 0
(2) GUY EAKIN PH D	(i) (ii)	114,843 0	0 0	216 0	18,741 0	29,509 0	163,309 0	0 0
(3) DAVID F MARKS CPA CMA	(i) (ii)	140,592 0	0 0	552 0	23,348 0	18,957 0	183,449 0	0 0

Schedule J (Form 990) 2010

Page 3

Part III

Supplemental Information

Complete this part to provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 4c, 5a, 5b, 6a, 6b, 7, and 8. Also complete this part for any additional information.

Identifier	Return Reference	Explanation

Schedule J (Form 990) 2010

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

NonCash Contributions

Complete if the organization answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization

AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Part I

Types of Property

	(a) Check if applicable	(b) Number of Contributions or items contributed	(c) Contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	8	20,448	FMV
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( DONATED FOOD )	X	1	5,372	FMV
26 Other ( )
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement ...

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1-28 that it

must hold for at least three years from the date of the initial contribution, and which is not required to be used

for exempt purposes for the entire holding period? ..................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any non-standard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell non-cash

contributions? ............................

32a

If "Yes," describe in Part II.

If the organization did not report revenues in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) 2010

Page 2

Part II

Supplemental Information. Complete this part to provide the information required by Part I, lines 30b,
32b, and 33. Also complete this part for any additional information.

Identifier	Return Reference	Explanation

Schedule M (Form 990) 2010

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.

OMB No. 1545-0047

2010

Open to Public
Inspection

Name of the organization

AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Identifier	Return Reference	Explanation
FORM 990, PART VI, SECTION B, LINE 11		A DRAFT OF THE FORM 990 SHALL BE DISTRIBUTED TO THE AUDIT COMMITTEE FOR REVIEW PRIOR TO BEING SUBMITTED TO THE IRS. THE DRAFT FORM 990 SHALL BE DISTRIBUTED EARLY ENOUGH TO PROVIDE EACH COMMITTEE MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUBMISSION OF QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FINAL FORM 990 SHALL BE DISTRIBUTED TO EACH BOARD MEMBER PRIOR TO BEING FILED WITH THE IRS. THE DRAFT AND FINAL FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-MAIL, OR FAX.
	FORM 990, PART VI, SECTION B, LINE 12C	AHAF HAS ALL EMPLOYEES, OFFICERS, AND DIRECTORS AGREE TO THE CODE OF CONDUCT WHICH INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST POLICY. EACH BOARD DIRECTOR AND OFFICER IS REQUIRED ANNUALLY TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT. IN ADDITION, ANY VIOLATION IS THE CONFLICT OF INTEREST POLICY IS REPORTED TO THE CHIEF COMPLIANCE OFFICER AND TO AHAF COUNSEL.
	FORM 990, PART VI, SECTION B, LINE 15A	THE AMERICAN HEALTH ASSISTANCE FOUNDATION (AHAF) BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES COMPENSATION FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS. ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE AHAF FISCAL YEAR. BEFORE APPROVING THE COMPENSATION OF THE CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY AHAF TO THE CEO IS REASONABLE IN LIGHT OF THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR THE FOUNDATION, IF APPLICABLE. THE CEO IS EVALUATED ANNUALLY BY THE BOARD THROUGH THE USE OF AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, (DEVELOPED WITH ADVICE FROM BOARD SOURCE) THAT INCLUDES A SELF ASSESSMENT AND BOARD ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES AND DELIVERABLES. THE BOARD OBTAINS AND CONSIDERS APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN LIKE CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD SHALL CONSIDER TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY AHAF TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE AHAF BOARD DISCUSSION AND DECISION CONCERNING THE CEOS COMPENSATION, THE CEO IS NOT PRESENT IN THE MEETING. THE BOARD SHALL SET FORTH THE BASIS FOR ITS DECISIONS WITH RESPECT TO COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DECISIONS ARE MADE, INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS FOR DETERMINING THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE IN LIGHT OF THE EVALUATION AND COMPARABILITY DATA.
	FORM 990, PART VI, SECTION C, LINE 19	AHAF MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF INCORPORATION AND BYLAWS, CONFLICT OF INTEREST POLICY, AUDITED FINANCIAL STATEMENTS AND IRS FORM 990 AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL REPORT, THE 1023 APPLICATION FORM WITH THE IRS, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION AND IRS FORM 990 ON THE AHAF WEBSITE.
CHANGES IN NET ASSETS OR FUND BALANCES:	FORM 990, PART XI, LINE 5:	NET UNREALIZED LOSSES ON INVESTMENTS: -1,015,819. RECOVERIES OF PRIOR YEAR GRANTS 80,908. CHANGE IN PRESENT VALUE OF GRANTS -8,922. SPECIAL EVENT NET INCOME -25,191. TOTAL TO FORM 990, PART XI, LINE 5: -969,024.
		SCHEDULE F, PART II, LINE 1, COLUMN (D): NAME OF ORGANIZATION: CARDIFF UNIVERSITY (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DR. JULIE ALBON ENTITLED: (G2011006) DISCS AT RISK: NOVEL OPTIC NERVE HEAD PHENOTYPING IN GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA CAN BE DIFFICULT CONDITION TO DETECT IN THE EARLIEST STAGES, AND IT IS VITAL THAT TREATMENT IS GIVEN AS SOON AS POSSIBLE TO PREVENT FURTHER DAMAGE TO THE EYE DEVELOPING. CLINICAL INSTRUMENTS ARE AVAILABLE TO EXAMINE THE OPTIC NERVE HEAD WHICH AIM TO DETECT THE PRESENCE OF GLAUCOMA AND TO MONITOR ITS PROGRESSION. THESE MACHINES ARE ABLE TO EXAMINE THE FRONT SURFACE OF THE OPTIC NERVE HEAD, BUT ONLY A FEW ARE ABLE TO PROVIDE INFORMATION ON WHAT IS HAPPENING BELOW THE SURFACE. IMPORTANT CHANGES OCCUR UNDER THE SURFACE OF THE OPTIC NERVE HEAD IN GLAUCOMA AND DRS. JULIE ALBON, JAMES MORGAN, RACHEL NORTH, WOLFGANG DREXLER, MICHAEL GIRARD, AND COLLEAGUES WILL USE A NEW MACHINE (A NOVEL TYPE OF OPTICAL COHERENCE TOMOGRAPHY OR OCT), WHICH IS ABLE TO EXAMINE BOTH THE FRONT SURFACE AND PARTS BELOW THE SURFACE IN DETAIL. AS THE OPTIC NERVE LEAVES THE EYE, IT TRAVELS THROUGH HOLES (OR PORES) IN THE LAMINA CRIBROSA. IN GLAUCOMA THERE ARE CHANGES TO THESE PORES AND THE SHAPE AND STRUCTURE OF THE LAMINA CRIBROSA. DETECTING THESE CHANGES COULD BE AN IMPORTANT SIGN THAT GLAUCOMA IS DEVELOPING OR GETTING WORSE. CURRENTLY IT IS NOT POSSIBLE FOR YOUR EYE DOCTOR TO EXAMINE THE LAMINA CRIBROSA. DR. ALBON AND COLLEAGUES WILL DEVELOP METHODS TO ANALYZE THESE CHANGES IN THE LAMINA CRIBROSA SO THAT AS THE NOVEL TECHNOLOGY BECOMES MORE AVAILABLE, RESEARCHERS AND EYE DOCTORS WILL BE ABLE TO DETECT MORE RAPIDLY CHANGES TO THE OPTIC NERVE HEAD DUE TO GLAUCOMA. GRANT AWARDED: $100,000 CARDIFF UNIVERSITY, CARDIFF, UNITED KINGDOM. NAME OF ORGANIZATION: THE CHINESE UNIVERSITY OF HONG KONG (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DR. CHRISTOPHER KAI-SHUN LEUNG ENTITLED: (G2011007) ROLE OF CX3CR1 IN MICROGLIA ACTIVATION AND RETINAL GANGLION CELL DEGENERATION IN GLAUCOMA - AN IN VIVO IMAGING STUDY. INVESTIGATOR'S SUMMARY: PHYSICAL CHANGES HAPPEN TO THE RETINA DURING GLAUCOMA. HOWEVER, THESE CHANGES CAN BE TOO SMALL TO SEE WITH A MAGNIFYING DEVICE IN AN EYE DOCTOR'S OFFICE. DR. CHRISTOPHER KAI-SHUN LEUNG AND COLLABORATORS WILL USE A MACHINE, CALLED A CONFOCAL LASER SCANNING OPHTHALMOSCOPE, TO TAKE LIVE PICTURES OF THE RETINAS IN MICE BEFORE AND AFTER THEY'VE BEEN GIVEN GLAUCOMA THROUGH INCREASING THEIR EYE PRESSURE. THEY SUSPECT THAT IMMUNE CELLS OF THE RETINA, CALLED MICROGLIA, COULD PROMOTE DAMAGE TO RETINAL NEURONS. TO TRACK THEIR ACTIVITY, THEY WILL SPECIFICALLY MAKE THESE CELLS GLOW IN THE DARK. THIS IS THE FIRST STUDY TO USE LIVE IMAGING TO DIRECTLY EXAMINE THE INTERACTIONS BETWEEN RETINAL NEURONS AND MICROGLIAL CELLS IN GLAUCOMA. IN THE FUTURE, THE RESULTS FROM THIS STUDY COULD BE USED TO DESIGN DRUGS TO PREVENT THE DAMAGE TO THE RETINA CAUSED BY MICROGLIA. GRANT AWARDED: $100,000 THE CHINESE UNIVERSITY OF HONG KONG, SHATIN, HONG KONG. NAME OF ORGANIZATION: IMPERIAL COLLEGE, LONDON (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DR. DARRYL RAY OVERBY ENTITLED: (G2011020) ARE MICE GOOD MODELS FOR IOP REGULATION IN HUMAN EYES?INVESTIGATOR'S SUMMARY: THE SUCCESS OF GLAUCOMA THERAPIES DEPENDS ON HOW WELL THEY LOWER PRESSURE IN THE EYE, AND SUCCESSFUL THERAPIES ARE OFTEN DEVELOPED WITH THE HELP OF ANIMAL MODELS SUCH AS MICE. HOWEVER, A DRUG FOUND TO LOWER PRESSURE IN MICE IS USELESS IN HUMANS IF THE MACHINERY CONTROLLING EYE PRESSURE IS DIFFERENT BETWEEN THE TWO SPECIES. RECENT STUDIES SUGGEST THAT PRESSURE REGULATION IN SOME STRAINS OF MICE RELIES MORE HEAVILY ON A SECONDARY OR "UVEOSCLERAL" PATHWAY FOR FLUID DRAINAGE FROM THE EYE, WHILE HUMAN PRESSURE REGULATION DEPENDS MORE ON THE PRIMARY OR "TRABECULAR" DRAINAGE PATHWAY. NOT ALL STRAINS OF MICE, HOWEVER, APPEAR TO EXHIBIT THE SAME PREFERENCE FOR DRAINAGE ROUTES, SUGGESTING THAT SOME STRAINS MAY BETTER REPRESENT THE TRABECULAR PRESSURE REGULATION AS OCCURS IN HUMANS. IN THIS PROJECT, DR. DARRYL OVERBY AND COLLEAGUES WILL EXAMINE GENETICALLY DISTINCT STRAINS OF MICE CHOSEN BASED UPON THEIR APPARENT DIFFERENCES IN DRAINAGE BEHAVIOUR, WITH THE GOAL TO IDENTIFY WHICH OF THESE STRAINS BEST MIMICS THE MACHINERY THAT CONTROLS PRESSURE IN HUMAN EYES. THIS IS AN IMPORTANT FIRST STEP TOWARDS ESTABLISHING A RELIABLE MOUSE MODEL THAT CAN BE USED TO DEVELOP BETTER THERAPIES THAT MORE SUCCESSFULLY LOWER PRESSURE AND PRESERVE VISION IN GLAUCOMA PATIENTS. GRANT AWARDED: $100,000 IMPERIAL COLLEGE LONDON, LONDON, UNITED KINGDOM.
		NAME OF ORGANIZATION: IMPERIAL COLLEGE, LONDON (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DR. MICHAEL JULIEN ALEXANDRE GIRARD ENTITLED: (G2011019) IN VIVO CORNEAL BIOMECHANICS: A BIOMARKER FOR GLAUCOMA? INVESTIGATOR'S SUMMARY: DRS. MICHAEL GIRARD AND NICK STROUTHIDIS WILL EXPLORE WHETHER THE STIFFNESS OF THE CORNEA, I.E., THE CLEAR "WINDOW" AT THE FRONT OF THE EYE, CAN PREDICT GLAUCOMA, A BLINDING OCULAR DISORDER CHARACTERIZED BY MECHANICAL DAMAGE AT THE BACK OF THE EYE. AN OPTICAL COHERENCE TOMOGRAPHY SCANNER WILL BE USED TO IMAGE IN GREAT DETAIL HOW ALL OCULAR TISSUES, INCLUDING BOTH THE FRONT AND BACK OF THE EYE, RESPOND TO A CHANGE IN INTRAOCULAR PRESSURE (THE PRESSURE THAT MAINTAINS THE SHAPE OF THE EYE). SUCH TESTING WILL ALLOW THEM, FOR THE FIRST TIME EVER, TO DEDUCE THE STIFFNESS OF THE ENTIRE EYE IN GLAUCOMA PATIENTS AND ESTABLISH A CORRELATION BETWEEN THESE STIFFNESS AND VISION LOSS. THEY ENVISION ONE DAY ASSESSING GLAUCOMA RISK BY MEASURING THE STIFFNESS OF PATIENTS' CORNEAS IN THE CLINIC. GRANT AWARDED: $100,000 IMPERIAL COLLEGE LONDON, UNITED KINGDOM. NAME OF ORGANIZATION: MAX-DELBRUECK CENTER FOR MOLECULAR MEDICINE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE REASEARCH BY DR. MICHAEL ROHE ENTITLED: (A2011601) ROLE OF SORLA IN TRANSPORT OF TRKB AND APP IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE PROTEIN CALLED SORLA WAS IDENTIFIED AS A RISK FACTOR IN ALZHEIMER'S DISEASE. IT HELPS WITH THE PRODUCTION OF BETA-AMYLOID WHICH FORMS THE CHARACTERISTIC PLAQUES IN ALZHEIMER'S DISEASE. ABNORMALLY HIGH LEVELS OF BETA-AMYLOID CAUSE THE DEATH OF NERVE CELLS IN PATIENTS, LEADING TO DEMENTIA. RECENTLY, DRS. MICHAEL ROHE, THOMAS WILLNOW, AND COLLABORATORS HAVE IDENTIFIED THE PROTECTIVE FACTOR BDNF TO ACTIVATE SORLA. REGULATION OF SORLA BY BDNF REDUCES THE AMOUNT OF BETA-AMYLOID. AN ABNORMALLY LOW LEVEL OF BDNF IS ASSOCIATED WITH ALZHEIMER'S DISEASE, BECAUSE THIS CAUSES LOW LEVELS OF SORLA THAT THEN LEADS TO HIGH LEVELS OF TOXIC BETA-AMYLOID. BETA-AMYLOID IS PRODUCED FROM THE PROTEIN APP, AND BDNF EXERTS ITS PROTECTIVE FUNCTION THROUGH BINDING TO THE PROTEIN TRKB. BOTH APP AND TRKB ARE BOUND BY SORLA THAT IS THOUGHT TO CONTROL THEIR TRANSPORT WITHIN THE CELL. TO SORT OUT THIS COMPLICATED INTERACTION OF PROTEINS, DR. ROHE AND COLLABORATORS WILL FIND OUT EXACTLY HOW SORLA WORKS IN CONCERT WITH APP AND TRKB. THEIR DISCOVERIES COULD POTENTIALLY LEAD TO A NEW DISEASE-MODIFYING TREATMENT DESIGNED TO INCREASE THE LEVELS OF SORLA IN THE BRAIN IN ORDER TO PREVENT THE RELEASE OF BETA-AMYLOID AND STOP PLAQUE FORMATION. GRANT AWARDED: $100,000 MAX-DELBRUECK CENTER FOR MOLECULAR MEDICINE, BERLIN, GERMANY. NAME OF ORGANIZATION: SINGAPORE EYE RESEARCH INSTITUTE (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DR. TIEN YIN WONG ENTITLED: (M2011068) GENETIC MARKERS OF ASIAN AGE RELATED MACULAR DEGENERATRION. INVESTIGATOR'S SUMMARY: PEOPLE WITH CAUCASIAN ETHNICITY (WHITE WITH EUROPEAN ANCESTRY) HAVE AN INCREASED RISK FOR AGE-RELATED MACULAR DEGENERATION (AMD). IN FACT, MANY OF THE CURRENTLY KNOWN RISK GENES WERE DISCOVERED BY STUDYING DNA FROM CAUCASIANS. USING FUNDS FROM A 2011 MACULAR DEGENERATION RESEARCH GRANT, DRS. TIEN YIN WONG, BELINDA CORNES, AND COLLABORATORS WILL FURTHER CHARACTERIZE THE GENETIC RISKS FOR AMD IN ASIANS, IN THE FIRST MAJOR POPULATION-BASED STUDY OF ITS KIND. THEY WILL COMPARE THE GENE DIFFERENCES AMONG PEOPLE OF THREE TYPES OF ETHNICITIES (CHINESE, MALAY, AND INDIAN) IN SINGAPORE, WHERE IT IS POSSIBLE FOR PEOPLE FROM THESE ETHNIC GROUPS TO HAVE SIMILAR SOCIOECONOMIC STATUS AND ENVIRONMENTAL EXPOSURES. THE DISCOVERY OF NEW RISK GENES FOR AMD MAY GIVE CLUES TO HOW THIS DISEASE STARTS AND/OR PROGRESSES, AND SUCH INSIGHT MAY LEAD TO PREVENTIONS AND TREATMENTS. GRANT AWARDED: $94,561 SINGAPORE EYE RESEARCH INSTITUTE, SINGAPORE.
		NAME OF ORGANIZATION: TRINITY COLLEGE, DUBLIN (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DR. PETER HUMPHRIES ENTITLED: (M2011034) THE INFLAMMASOME AND NOVEL THERAPEUTIC TARGETS IN AMD. INVESTIGATOR'S SUMMARY: THE BODY'S IMMUNE SYSTEM CAN WARD OFF ATTACKS BY BACTERIA, VIRUSES AND OTHER EXTERNAL THREATS. HOWEVER, IT ALSO HAS SYSTEMS IN PLACE TO RESPOND TO INTERNAL THREATS, LIKE THE BUILD-UP OF DRUSENTINY WASTE DEPOSITS IN THE BACK OF THE EYE-THAT HAPPENS IN AGE-RELATED MACULAR DEGENERATION (AMD). IN PREVIOUS STUDIES, DRS. PETER HUMPHRIES, MATTHEW CAMPBELL, AND COLLEAGUES HAVE OBSERVED THAT DRUSEN CAN TRIGGER A LOCALIZED IMMUNE RESPONSE BY A COLLECTION OF PROTEINS CALLED THE "INFLAMMASOME." IN THIS PROJECT, THEY WILL DETERMINE WHY THIS OCCURS AND WHAT COMPONENTS OF THE INFLAMMASOME PLAY KEY ROLES IN CAUSING AMD. THIS GROUP WILL ALSO SCREEN A RANGE OF DRUGS THAT COULD TIP THE PROTEIN COMPOSITION OF DRUSEN TO A HEALTHY RATIO TO BETTER-TREAT AMD. MANY OF THE DRUGS THEY WILL USE IN THE SCREEN ALREADY HAVE REGULATORY APPROVAL FOR HUMAN USE, WHICH MAY ACCELERATE THEIR ENTRY INTO HUMAN CLINICAL TRIALS. GRANT AWARDED: $100,000 TRINITY COLLEGE DUBLIN, DUBLIN, IRELAND.
		SCHEDULE I, PART II, LINE 1, COLUMN (H): NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PENNSYLVANIA (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. PAUL H. AXELSEN ENTITLED: (A2011044) OXIDATIVE LIPID DEGRADATION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: WE ALL NEED OXYGEN TO SURVIVE, BUT OXYGEN CAN REACT WITH CHEMICALS IN THE BODY TO CREATE HARMFUL BYPRODUCTS AND "OXIDATIVE STRESS." DR. PAUL AXELSEN AND COLLEAGUES WILL STUDY THE ROLE OF OXIDATIVE STRESS IN ALZHEIMER'S DISEASE. THEY WILL ATTEMPT TO DETERMINE HOW OXIDATIVE STRESS CAUSES CHEMICAL CHANGES IN DIETARY FATS (INCLUDING OMEGA-3 AND OMEGA-6) THAT CAN DAMAGE BRAIN AMYLOID PROTEINS. THESE RESEARCHERS WILL USE SPECIAL TRACERS ON THE FATS TO DETECT THE CHANGES IN DIETARY FATS AND IN THE AMYLOID PROTEINS OF MOUSE MODELS OF ALZHEIMER'S DISEASE AND OXIDATIVE STRESS. THE RESULTS FROM THIS STUDY MAY GIVE IDEAS ON HOW TO FIGHT OXIDATIVE STRESS IN THE HUMAN BRAIN. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MIAMI (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. MARGARET A. PERICAK-VANCE ENTITLED: (A2011048) WHOLE EXOME SEQUENCING IN ALZHEIMER DISEASE. INVESTIGATOR'S SUMMARY: THERE ARE A NUMBER OF GENES THAT ARE ASSOCIATED WITH ALZHEIMER'S DISEASE, BUT THERE ARE MANY MORE YET TO BE DISCOVERED. IN THIS PROPOSED PROJECT, DRS. MARGARET A. PERICAK-VANCE, STEPHAN ZHUCHNER, AND COLLEAGUES WILL STUDY LARGE FAMILIES WITH ALZHEIMER'S, TO INCREASE THE CHANCES OF DISCOVERING A STRONG GENETIC RISK OF DEVELOPING THIS DISEASE. THESE RESEARCHERS WILL USE NEW GENE READING TECHNIQUES TO LOOK AT THE "WHOLE EXOME" (OR THE DNA SPELLING OF THE MOST-USED BOOKS IN A PERSON'S GENETIC LIBRARY) TO FILTER OUT A SMALL SET OF CANDIDATES. THESE CANDIDATES WILL THEN BE DOUBLE-CHECKED BY CONFIRMING THEIR IDENTITIES IN THE DNA FROM OTHER GROUPS OF PEOPLE WITH ALZHIEMER'S. KNOWING THE IDENTITY OF ALZHEIMER'S GENES COULD AID WITH INITIAL DIAGNOSES AND LEAD TO FUTURE PREVENTIONS AND TREATMENTS. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CHICAGO (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. SANGRAM S. SISODIA ENTITLED: (A2011054) STRUCTURE AND FUNCTIONAL ANALYSIS OF NICASTRIN. INVESTIGATOR'S SUMMARY: BETA-AMYLOID, THE STICKY PROTEIN THAT IS THE MAIN COMPONENT OF BRAIN PLAQUES IN ALZHEIMER'S DISEASE, IS CREATED BY CLIPPING IT FROM A BIGGER PROTEIN, CALLED BETA-AMYLOID PRECURSOR PROTEIN (APP). THIS CLIPPING OF APP IS DONE BY GAMMA SECRETASE, A BUNDLE OF PROTEINS THAT INCLUDES PRESENILIN 1 OR 2, APH-1, PEN-2, AND NICASTRIN (NCT). NCT IS THE PART OF THE BUNDLE THAT RECOGNIZES AND PULLS INTO THE COMPLEX MANY OF THE PROTEINS, INCLUDING APP, THAT ARE THEN PROCESSED BY THE REST OF THE GAMMA SECRETASE PROTEINS. DRS. SANGRAM SISODIA, SHOHEI KOIDE, AND COLLABORATORS WILL STUDY THE SHAPE OF NCT TO BETTER UNDERSTAND HOW IT PARTNERS WITH OTHER PROTEINS. THEY WILL MAKE ANTIBODIES THAT BIND LIKE A LOCK AND KEY TO DIFFERENT PARTS OF NCT TO AID IN THEIR ANALYSIS. ONCE THE SHAPE OF NCT IS DETERMINED, THE NEXT STEP WILL BE TO DESIGN AND TEST NEW DRUGS TO SPECIFICALLY BLOCK NCT FROM BINDING TO APP AND, AS A RESULT, PREVENT THE CREATION OF BETA-AMYLOID.
		NAME OF ORGANIZATION OR GOVERNMEN: MEDICAL UNIVERSITY OF SOUTH CAROLINA (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. NARAYAN R. BHAT ENTITLED: (A2011081) ROLE OF A STRESS KINASE IN AD PATHOGENESIS. INVESTIGATOR'S SUMMARY: THE PROTEIN CALLED "P38 MAP KINASE" IS IMPORTANT FOR MANY FUNCTIONS IN THE BODY, AND PROBLEMS WITH THIS PROTEIN CAN CAUSE INFLAMMATION AND INTERRUPT NERVE CELL COMMUNICATION IN ALZHEIMER'S DISEASE. DR. NARAYAN BHAT AND COLLABORATORS PLAN TO CREATE AND STUDY A NEW MOUSE MODEL OF ALZHEIMER'S. TO MAKE THIS MODEL, THEY WILL CHANGE THE P38 MAP KINASE PROTEINS IN TWO PARTS OF THE BRAIN, NAMELY IN IMMUNE CELLS CALLED MICROGLIA, AND AT THE POINTS WHERE THE NERVE CELLS COMMUNICATE, CALLED SYNAPSES. THE CHANGES IN MICROGLIA, SYNAPSES AND OVERALL BRAIN HEALTH WILL BE MONITORED BY STATE-OF-THE-ART TECHNIQUES, INCLUDING LABELING CELLS WITH A SPECIAL DYE AND EXAMINING THEM UNDER A SPECIAL MICROSCOPE. INFORMATION OBTAINED FROM THIS STUDY MAY HELP TO DIRECT FUTURE DRUG THERAPIES. NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. EUGENIA TRUSHINA ENTITLED: (A2011084) ROLE OF HISTONE DEACETYLASE IN AD MITOCHONDRIAL DYSFUNCTION. INVESTIGATOR'S SUMMARY: HISTONE DEACETYLASE 1 (HDAC1) IS A PROTEIN THAT CONTROLS GENE ACTIVITY. PROBLEMS WITH HDAC1 CAN BOTH DISRUPT THE ACTIVITIES OF OTHER GENES, AND CAN PROMOTE CELL DEATH BY DISRUPTING MOVEMENT OF THE MITOCHONDRIA, THE CELL'S "ENERGY POWERHOUSES." DR. EUGENIA TRUSHINA, DR. JOSEPH PODUSLO, AND COLLEAGUES WILL LOOK FOR WHAT SPECIFICALLY CAUSES THE PROBLEM WITH MITOCHONDRIAL MOVEMENT. IN PARTICULAR, THEY'LL LOOK AT THE EFFECT OF BETA-AMYLOID PROTEINS ON MITOCHONDRIAL MOTILITY IN CULTURED CELLS AND IN BRAIN SLICES FROM MICE WITH ALZHIEMER'S. ONCE THEY PINPOINT THE MECHANISM OF DYSFUNCTION, THE NEXT STEP WOULD BE TO CREATE AND TEST DRUGS THAT RESTORE THE MITOCHONDRIAL TRANSPORT AND, HOPEFULLY, PREVENT PROGRESSION OF THE DISEASE. NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. BRADLEY T. HYMAN ENTITLED: (A2011086) A MODEL OF EARLY ALZHEIMER DISEASE. INVESTIGATOR'S SUMMARY: THE ENTORHINAL CORTEX IS THE PART OF THE BRAIN THAT IS RESPONSIBLE FOR COMMUNICATIONS TO AND FROM THE HIPPOCAMPUS (WHICH, IN TURN, IS THE PART OF THE BRAIN THAT'S IMPORTANT FOR CREATING AND MAINTAINING MEMORIES). IN ALZHEIMER'S DISEASE, BRAIN LESIONS TEND TO START IN THE ENTORHINNAL CORTEX AND "SPREAD" TO OTHER PARTS, WITH DEVASTATING EFFECTS. ONE OF THE LESIONS FORMED IN ALZHEIMER'S ARE CALLED "TANGLES" THAT CONTAIN TAU PROTEIN. DRS. BRADLEY HYMAN, TERESA GOMEZ-ISLA, AND COLLEAGUES WILL STUDY HOW ALZHEIMER'S AFFECTS THE ENTORHINNAL COMPLEX AND HOW THE LESIONS SPREAD FROM THIS INITIAL PLACE OF DAMAGE TO OTHER PARTS OF THE BRAIN. THEY WILL CREATE AND STUDY A NEW MOUSE MODEL OF ALZHEIMER'S WHERE TAU PROTEIN IS DIRECTED TO BE EXPRESSED ONLY IN THE ENTORHINNAL CORTEX. AMYLOID, THE OTHER KEY MOLECULE IN ALZHEIMER'S AFFECTS THE CONNECTIONS BETWEEN NEURONS THAT ORIGINATE IN THE ENTORHINAL CORTEX. OTHER MOUSE MODELS DON'T ADDRESS THE SPREAD OF LESIONS, BUT THIS MODEL IS DESIGNED TO ISOLATE THIS KEY PART OF PROGRESSION TO LATER STAGES OF ALZHEIMER'S. IN THE FUTURE, THIS MODEL COULD THEN BE USED FOR TESTING TREATMENTS TO HALT THE SPREAD OF THE LESIONS, AND THE INTERACTION OF LESIONS, BEFORE THEY CAUSE CELL DAMAGE AND DEATH IN OTHER PARTS OF THE BRAIN.
		NAME OF ORGANIZATION OR GOVERNMENT: CASE WESTERN RESERVE UNIVERSITY (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. GARY E. LANDRETH ENTITLED: (A2011102) RXR: A THERAPEUTIC TARGET IN NEURODEGENERATIVE DISEASE. INVESTIGATOR'S SUMMARY: A DRUG THAT IS TAKEN BY MOUTH HAS BEEN SHOWN TO LOWER BETA-AMYLOID LEVELS AND REMOVE EXISTING PLAQUES IN THE BRAINS OF MOUSE MODELS WITH ALZHEIMER'S DISEASE. IN THIS RESEARCH PROJECT, DR. GARY LANDRETH AND COLLEAGUES WILL BE TESTING WHETHER THIS DRUG ALSO CAN PREVENT DAMAGE TO BRAIN CELLS IN ANOTHER TYPE OF ALZHEIMER'S DISEASE MOUSE. IF IT DOES HAVE PROTECTIVE EFFECTS, IT COULD BE PUT ON THE FAST TRACK FOR HUMAN CLINICAL TRIALS. THIS DRUG HOLDS PARTICULAR PROMISE DUE TO ITS DISEASE MODIFYING ACTIONS. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PENNSYLVANIA (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. KURT R. BRUNDEN ENTITLED: (A2011303) IN VIVO TESTING OF NOVEL TAU FIBRILLIZATION INHIBITORS. INVESTIGATOR'S SUMMARY: ONE OF THE HALLMARKS OF ALZHEIMER'S DISEASE IS THE UNNATURAL CLUMPING OF MISFOLDED TAU PROTEINS INTO TANGLES IN THE BRAIN. THESE TANGLES, ALONG WITH BETA-AMYLOID PLAQUES, CAUSE BRAIN CELL DEATH AND PROBLEMS WITH MEMORY AND OTHER IMPORTANT ACTIVITIES. DR. KURT BRUNDEN AND COLLEAGUES WILL BE TESTING A NUMBER OF DRUGS ON ALZHEIMER'S DISEASE MICE TO SEE WHETHER ONE OF THEM CAN PREVENT TAU FROM CLUMPING. THE DRUG THAT WORKS IN MICE MAY BE A CANDIDATE FOR FUTURE ALZHEIMER'S DISEASE HUMAN CLINICAL TRIALS. NAME OF ORGANIZATION OR GOVERNMENT: ROCKEFELLER UNIVERSITY (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. MARTA CORTES-CANTELI ENTITLED: (A2011310) ROLE OF FIBRINOGEN IN ALZHEIMER'S DISEASE NEURONAL AND SYNAPTIC LOSS. INVESTIGATOR'S SUMMARY: PEOPLE WHO HAVE ALZHEIMER'S DISEASE CAN ALSO HAVE BLOCKED BRAIN BLOOD VESSELS THAT ACCELERATE PROBLEMS WITH MEMORY AND OTHER BRAIN ACTIVITIES. IN A PREVIOUS AHAF GRANT, DR. MARTA CORTES-CANTELI AND COLLABORATORS SHOWED THAT BETA-AMYLOID PROTEIN BINDS TO THE BLOOD CLOTTING PROTEIN, CALLED FIBRINOGEN, AND PREVENTS IT FROM BUSTING-UP CLOTS. THE RESULTING BLOCK IN BLOOD FLOW CAN LEAD TO INCREASED INFLAMMATION, LOSS OF COMMUNICATION BETWEEN NERVES, AND DEATH IN THOSE PARTS OF THE BRAIN. MOREOVER, DECREASING THE AMOUNT OF FIBRINOGEN HAS BEEN SHOWN TO REDUCE MEMORY LOSS IN MOUSE MODELS OF ALZHEIMER'S DISEASE. IN THIS PROJECT, DR. CORTES-CANTELI WILL STUDY MOUSE AND HUMAN BRAIN SAMPLES TO DETERMINE WHETHER FIBRINOGEN IS FOUND IN THE SAME LOCATIONS WHERE NERVE CELLS STOP COMMUNICATING. THEY WILL ALSO TREAT ALZHEIMER'S DISEASE MICE WITH DRUGS THAT DECREASE FIBRINOGEN LEVELS TO CHECK WHETHER THE NEURONS COMMUNICATE BETTER ONCE CLOTS ARE REMOVED AND BLOOD FLOW HAS BEEN RESTORED. IT IS EXTREMELY IMPORTANT TO PREVENT NEURONS FROM DYING, AND THIS WORK WILL GIVE CLUES ON HOW TO PREVENT IT AND WILL SUPPORT THE DESIGN OF THERAPEUTIC STRATEGIES AIMED AT BLOCKING OR DECREASING THE BLOOD CLOT FORMATION OBSERVED IN ALZHEIMER'S DISEASE.
		NAME OF ORGANIZATION OR GOVERNMENT: RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. AT IBR (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. MASUO OHNO ENTITLED: (A2011311) EIF2A KINASE GCN2 AS A TARGET FOR ALZHEIMER'S THERAPY. INVESTIGATOR'S SUMMARY: CHANGES IN THE ACTIVITY OF SPECIFIC BRAIN PROTEINS LEAD TO AN INCREASE IN BETA-AMYLOID PROTEIN, CELL DEATH, AND LOSS OF MEMORY IN ALZHEIMER'S DISEASE. DR. MASUO OHNO AND COLLEAGUES ARE LOOKING AT THREE PROTEIN "PLAYERS" THAT INCREASE THE LEVELS OF BETA-AMYLOID EXPRESSION, INCLUDING GCN2, EIF2ALPHA, AND BACE1. THE GCN2 PROTEIN ADDS A SPECIAL CHEMICAL GROUP, CALLED A "PHOSPHATE", TO THE EIF2ALPHA PROTEIN. THIS CHANGED EIF2ALPHA THEN ELEVATES BACE1, A KEY ENZYME RESPONSIBLE FOR BETA-AMYLOID PRODUCTION. THE CHANGED EIF2ALPHA ALSO SUPPRESSES THE ACTIVITY OF THE CREB PROTEIN. CREB HELPS MEMORIES TO FORM, SO REDUCING ITS ACTIVITY IS BAD NEWS FOR THE BRAIN. TO BREAK THIS DUAL HARMFUL CYCLE, THEY WILL REMOVE THE GCN2 GENE FROM MICE WITH ALZHEIMER'S DISEASE SO THAT A PHOSPHATE WON'T BE ADDED TO EIF2ALPHA AND, THEREFORE, WON'T ELEVATE BACE1 OR SUPPRESS CREB. STOPPING THE BACE1 ELEVATION AND THE LOSS OF CREB ACTIVITY COULD IMPROVE THE MEMORIES OF THESE MICE. THEIR DISCOVERIES WILL HELP TO UNDERSTAND THE KEY CHEMICAL CHANGES THAT HAPPEN AS ALZHEIMER'S DISEASE PROGRESSES, AND COULD LEAD TO NEW POSSIBILITIES FOR DISEASE-MODIFYING DRUGS. NAME OF ORGANIZATION OR GOVERNMENT: RENSSELAER POLYTECHNIC INSTITUTE (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. PETER MATTHEW TESSIER ENTITLED: (A2011355) STRUCTURE OF ABETA C-TERMINAL DOMAIN IN TOXIC OLIGOMERS. INVESTIGATOR'S SUMMARY: A PROTEIN CALLED AMYLOID PRECURSOR PROTEIN (APP) CAN BE CUT INTO TOXIC AND NON-TOXIC FORMS OF BETA-AMYLOID. THE TOXIC FORMS OF BETA-AMYLOID (CALLED BETA-AMYLOID 42) MISFOLD AND CLUMP TOGETHER INTO BRAIN PLAQUES, A HALLMARK OF ALZHEIMER'S DISEASE. OTHER BETA-AMYLOID FRAGMENTS OF APP DO NOT MISFOLD. DR. PETER TESSIER AND COLLABORATORS WILL USE NEW DETECTION METHODS TO STUDY THE DIFFERENCES BETWEEN TOXIC AND NON-TOXIC FOLDING OF BETA-AMYLOID PROTEINS IN ALZHEIMER'S DISEASE. THEIR LONG TERM GOAL IS TO DESIGN A DRUG THAT COULD PREVENT THIS FOLDING AND CLUMPING. IF SUCCESSFUL, THIS METHOD COULD BE APPLIED TO TOXIC MISFOLDING THAT HAPPENS IN OTHER NEURODEGENERATIVE DISEASES, LIKE PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, AND PRION DISEASE (INCLUDING CREUTZFELD-JACOB OR "MAD COW" DISEASE). NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY KEN A. PALLER, PH. D. ENTITLED: (A2011362) ENTRAINMENT OF SLOW-WAVE SLEEP TO IMPROVE MEMORY IN MCI. INVESTIGATOR'S SUMMARY: PROFESSOR PALLER AND HIS COLLABORATORS HAVE PREVIOUSLY INVESTIGATED SLEEP PROBLEMS IN ALZHEIMER'S DISEASE. IN ONE STUDY, LED BY DR. CARMEN WESTERBERG, PATIENTS WHO HAD RECEIVED A DIAGNOSIS OF AMNESTIC MILD COGNITIVE IMPAIRMENT (WHICH CAN PROGRESS TO ALZHEIMER'S DISEASE AND IS ALSO KNOWN AS MCI) REPORTED THAT THEIR SLEEP WAS NOT AS RESTFUL AS NORMAL. A SUBSEQUENT STUDY SHOWED THAT PHYSIOLOGICAL MEASURES OF SLEEP IN PATIENTS WITH MCI WERE ALTERED FROM WHAT WOULD BE EXPECTED BASED ON THEIR AGE. PROMINENT REDUCTIONS WERE OBSERVED IN DEEP SLEEP, WHICH IS WHEN SLOW WAVES ARE APPARENT IN MEASURES OF BRAIN ELECTRICAL ACTIVITY. ANALYSES OF MEMORY SUGGESTED THAT REDUCED DEEP SLEEP COULD HAVE CONTRIBUTED TO PATIENTS' DECLINING MEMORY ABILITIES. THE PARTICULAR TYPE OF MEMORY THAT IS DEFICIENT IN AMNESTIC MCI CONCERNS REMEMBERING FACTS AND EVENTS AND IS KNOWN AS DECLARATIVE MEMORY. NEW RESEARCH IN PROFESSOR PALLER'S LAB IS TESTING THE HYPOTHESIS THAT POOR SLEEP IS AN IMPORTANT FACTOR CONTRIBUTING TO MEMORY DYSFUNCTION IN THESE PATIENTS. EACH PARTICIPANT IN THIS RESEARCH WILL LEARN SOME FACTUAL MATERIAL PRIOR TO AN AFTERNOON NAP. EEG RECORDINGS WILL BE USED TO VERIFY SLEEP IN EACH PARTICIPANT AND ALLOW FOR ANALYSES OF BRAIN ACTIVITY DURING SLEEP. DURING SOME OF THESE NAPS, ARTIFICIAL ELECTRICAL SIGNALS WILL BE USED TO STIMULATE DEEP SLEEP. BY PROMOTING THE TYPE OF BRAIN ACTIVITY THAT OCCURS DURING DEEP SLEEP, THE INVESTIGATORS EXPECT TO ALSO IMPROVE MEMORY STORAGE. AFTER PARTICIPANTS WAKE UP, MEMORY TESTS WILL BE ADMINISTERED IN ORDER TO DETERMINE WHETHER RECALL IS SUPERIOR WITH VERSUS WITHOUT STIMULATION DURING SLEEP. THE RESULTS WILL INCREASE UNDERSTANDING OF THE EXTENT TO WHICH HEALTHY MEMORY FUNCTION DEPENDS ON BRAIN EVENTS THAT TAKE PLACE DURING SLEEP, AND WILL HAVE RAMIFICATIONS FOR EFFORTS TO IMPROVE MEMORY IN PEOPLE WHO ARE SUFFERING FROM A DECLINE IN MEMORY FUNCTION.
		NAME OF ORGANIZATION OR GOVERNMENT: MEDICAL COLLEGE OF WISCONSIN (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. NASHAAT Z. GERGES ENTITLED: (A2011367) BETA AMYLOID-INDUCED SYNAPTIC PLASTICITY IMBALANCE AND NEUROGRANIN. INVESTIGATOR'S SUMMARY: PREVIOUS STUDIES HAVE FOUND THAT THE ALZHEIMER'S DISEASE BETA-AMYLOID PROTEIN NEGATIVELY INFLUENCES BRAIN CELLS (NEURONS) AND RESULTS IN A COMMUNICATION BREAKDOWN BY CAUSING A LOSS OF "PLASTICITY" AT THE SYNAPSES (THE PLACE WHERE NEURONS MEET), LEADING TO LEARNING AND MEMORY LOSS. IN A PREVIOUS STUDY, DR. NASHAAT GERGES AND COLLEAGUES HAVE SHOWN THAT INCREASING NEUROGRANIN ENHANCES THE ABILITY OF THE SYNAPSES TO COMMUNICATE. IN THIS PROJECT, THEY WILL EXPLORE THE POSSIBILITY THAT NEUROGRANIN MAY REVERSE THE NEGATIVE EFFECT OF BETA AMYLOID ON SYNAPTIC PLASTICITY. THEY WILL USE A SPECIAL TECHNIQUE THAT GROWS NEURONS IN A DISH, GIVING EASY ACCESS FOR TREATMENTS AND ANALYSIS OF RESULTS. IF SUCCESSFUL, THIS COULD LEAD TO FUTURE THERAPIES FOR INDIVIDUALS WITH ALZHEIMER'S DISEASE. NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. MICHAEL ANTHONY DETURE ENTITLED: (A2011368) RESTORATION OF THE 3R:4R TAU EQUILIBRIUM AS A TAUOPATHY THERAPY. INVESTIGATOR'S SUMMARY: TWO HALLMARKS OF ALZHEIME'S DISEASE ARE PLAQUES AND TANGLES-PROTEIN DEPOSITS IN THE BRAIN THAT CAN LEAD TO NERVE CELL DEATH AND MEMORY PROBLEMS. TANGLES ARE FORMED WHEN A CERTAIN TYPE OF PROTEIN, CALLED TAU, BECOMES STICKY AND FORMS MESSY BLOBS INSIDE OF NERVE CELLS. DR. MICHAEL DETURE AND COLLABORATORS THINK THAT TANGLES ARE FORMED WHEN THE NATURAL BALANCE OF TWO VERSIONS OF TAU TIP TO THE STICKY FORM, AND THAT BY SETTING THE BALANCE STRAIGHT AGAIN THEY CAN PREVENT TANGLES FROM FORMING. IN THIS PROJECT, THEY WILL GENETICALLY INCREASE THE EXPRESSION LEVELS OF THE NON-STICKY FORM OF TAU IN A MOUSE MODEL OF ALZHEIMER'S. THIS SHOULD RESTORE THE BALANCE OF THE RATIOS AND PERHAPS PREVENT THE TANGLES FROM FORMING. IF THEY DO FIND A WAY TO RESTORE THE BALANCE OF TAU EXPRESSION, THEN THIS COULD BE AN EXCITING NEW TREATMENT TO BLOCK OR REVERSE THE FORMATION OF TANGLES IN INDIVIDUALS WITH ALZHEIMER'S DISEASE. NAME OF ORGANIZATION OR GOVERNMENT: LERNER RESEARCH INSTITUTE, CLEVELAND CLINIC FOUNDATION (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. KIRAN BHASKAR ENTITLED: (A2011372) ROLE OF P38 MAPK IN THE MICROGLIAL-MEDIATED ALZHEIMER'S DISEASE TAU PATHOLOGY. INVESTIGATOR'S SUMMARY: DR. KIRAN BHASKAR'S LABORATORY HAS ALREADY SHOWN THAT INFLAMMATION BY A PARTICULAR IMMUNE CELL, CALLED MICROGLIA, CAN START AND ACCELERATE TANGLES IN CELL CULTURES AND IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE. A PROTEIN, CALLED P38 MAPK, IS INVOLVED WITH THIS INFLAMMATION AND SUBSEQUENT CREATION OF TANGLES. DR. BHASKAR AND COLLABORATORS WILL DETERMINE WHETHER A DRUG, CALLED 069A, WILL TARGET THE P38 MAPK PROTEIN AND PREVENT TANGLES FROM FORMING IN THE BRAINS OF MICE WITH A HUMAN FORM OF ALZHEIMER'S DISEASE. COLLABORATORS HAVE ADAPTED THE 069A DRUG TO ENABLE IT TO BE TAKEN BY MOUTH AND GET INTO THE BRAIN. IF AN EXPERIMENTAL INCREASE IN P38 MAPK CAUSES AN INCREASE IN TANGLES AND INTERVENTION WITH 069A PREVENTS IT, THEN A FUTURE GOAL WOULD BE TO TEST THIS DRUG IN A HUMAN CLINICAL TRIAL FOR TREATMENT OF ALZHEIMER'S DISEASE.
		NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO (H) PURPOSE OF GRANT OR ASSISTANCE: ALZHEIMER'S DISEASE REASEARCH BY DR. BIJU K. CHANDU ENTITLED: (A2011615) IPS-DERIVED MICROGLIA-BASED GENE THERAPY FOR ALZHEIMER'S. INVESTIGATOR'S SUMMARY: THERAPIES USING YOUR OWN (SELF-DERIVED) BONE MARROW CELLS HAVE PROMISE FOR TREATING MANY DIFFERENT DISEASES, INCLUDING ALZHEIMER'S DISEASE. THIS TYPE OF SELF-RECOGNIZING STEM CELL THERAPY HAS AN INCREASED CHANCE OF SUCCESS, BECAUSE ONE CAN AVOID THE PESKY PROBLEM OF THE IMMUNE SYSTEM LABELING THE CELLS AS FOREIGN INVADERS AND KILLING THEM BEFORE THEY HAVE A CHANCE TO WORK. DR. BIJU CHANDU AND COLLABORATORS WILL BE TESTING A NEW BONE MARROW CELL TREATMENT FOR ALZHEIMER'S DISEASE. FIRST, THEY WILL ISOLATE WHITE BLOOD CELLS THAT ROAM FREELY IN THE EASILY-ACCESSIBLE BLOOD VESSELS. THESE CELLS WILL IN TURN BE GENETICALLY MODIFIED TO BECOME BONE MARROW CELLS AND RE-PURPOSED TO RELEASE ANTI-ALZHEIMER'S DISEASE DRUGS. THE MODIFIED CELLS ARE INJECTED BACK IN THE BLOOD STREAM, WHERE THEY MIGRATE TO THE PARTS OF THE BRAIN THAT REQUIRE TREATMENT. AFTER THIS NEW TREATMENT IS TESTED IN CELL CULTURE AND ANIMALS IN THIS PROJECT, THE RESEARCHERS MAY THEN DECIDE TO MOVE THIS TECHNIQUE INTO HUMAN CLINICAL TRIALS. NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY (H) PURPOSE OF GRANT OR ASSISTANCE: NATIONAL GLAUCOMA RESEARCH BY DR. BRIAN CHRISTOPHER SAMUELS ENTITLED: (G2011012) HYPOTHALAMIC CONTROL OF TRANSLAMINAR PRESSURE GRADIENTS. INVESTIGATOR'S SUMMARY: AN INCREASE IN EYE PRESSURE CAN DAMAGE THE OPTIC NERVE AND LEAD TO GLAUCOMA. HOWEVER, NEW STUDIES HAVE SHOWN THAT AN EYE PRESSURE CHANGE MAY NOT BE THE ONLY SITUATION THAT CAN CAUSE AN INCREASED RISK OF DEVELOPING GLAUCOMA. DR. BRIAN SAMUELS AND COLLEAGUES WILL STUDY HOW CERTAIN CELLS WITHIN THE BRAIN CONTROLS THE PRESSURE INSIDE BOTH THE EYE AND THE BRAIN, BECAUSE THEY BELIEVE THAT CHANGES TO THE PRESSURE IN THE BRAIN MAY BE JUST AS IMPORTANT IN GLAUCOMA. USING RAT MODELS, THEY WILL IDENTIFY THE EXACT LOCATION OF THE BRAIN CELLS THAT CONTROL SOME OF THE DAILY CHANGES IN THE EYE AND BRAIN PRESSURE. ONCE THEY LOCATE THESE BRAIN CELLS, THEY COULD BE THE TARGET FOR NEW GLAUCOMA THERAPIES. IN ADDITION, DISCOVERING HOW THE BRAIN CELLS CONTROL BOTH EYE AND BRAIN PRESSURE COULD LEAD TO NEW TREATMENTS OF OTHER DISEASES THAT AFFECT THE BRAIN AND NERVES. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (H) PURPOSE OF GRANT OR ASSISTANCE: NATIONAL GLAUCOMA RESEARCH BY DR. WEIMING MAO ENTITLED: (G2011032) CROSSTALK OF TGF-BETA AND WNT PATHWAYS IN THE TRABECULAR MMESHWORK. INVESTIGATOR'S SUMMARY: CHANGES IN TWO NETWORKS OF PROTEINS-NAMED THE TGF-BETA AND WNT PATHWAYS-CAN PROMOTE "CLOGS" IN THE DRAINAGE SYSTEM OF THE EYE-THE TRABECULAR MESHWORK (TM). THESE CLOGS CAUSE AN INCREASE IN EYE PRESSURE AND MAY LEAD TO GLAUCOMA. DR. WEIMING MAO AND COLLEAGUES WILL FIRST SCREEN THE TGF-BETA AND WNT PATHWAYS TO IDENTIFY THE SPECIFIC PROTEINS THAT ARE INVOLVED IN CROSS-TALK BETWEEN THESE TWO NETWORKS. THEN, THEY WILL TEST WHETHER THE TM DRAIN STRUCTURE AND EYE PRESSURE CAN BE BROUGHT BACK TO NORMAL AFTER GENETICALLY INCREASING OR DECREASING THE LEVELS OF THESE CROSS-TALK PROTEINS IN CULTURED CELLS AND ANIMAL MODELS OF GLAUCOMA. IF ONE OF THE PROTEINS ENDS UP INFLUENCING EYE PRESSURE THROUGH THE TGF-BETA AND WNT PATHWAYS, THEN A DRUG COULD BE DESIGNED TO BETTER CONTROL EYE PRESSURE IN GLAUCOMA.
		NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY (H) PURPOSE OF GRANT OR ASSISTANCE: NATIONAL GLAUCOMA RESEARCH BY DR. XIAORONG LIU ENTITLED: (G2011033) NEUROTROPHIC MECHANISMS IN OCULAR HYPERTENSION MICE. INVESTIGATOR'S SUMMARY: A GROUP OF NERVE SURVIVAL FACTORS, CALLED NEUROTROPHINS, WILL BE TESTED IN A MOUSE MODEL OF GLAUCOMA TO SEE IF THEY CAN RESCUE THE STRUCTURE AND FUNCTION OF THE OPTIC NERVE CELLS BEFORE THEIR DEATH. DR. XIAORONG LIU AND COLLEAGUES WILL USE MICE WITH HIGH EYE PRESSURE TO MIMIC THE HUMAN HIGH-TENSION GLAUCOMA IN THEIR TESTS. THEY WILL USE GENETIC TECHNIQUES TO SPECIFICALLY EXAMINE HOW TWO NEUROTROPHINS-CALLED BDNF AND NT- 3-CONTRIBUTE TO PROTECT RETINAL CELL STRUCTURE AND VISUAL BEHAVIORS IN MICE WITH HIGH EYE PRESSURE. THE RESULTS WILL THUS PROVIDE INSIGHT INTO WHETHER BDNF AND NT-3 ARE GOOD CANDIDATES FOR DRUG TARGETING TO PREVENT THE OPTIC NERVE CELL DAMAGE THAT OCCURS IN GLAUCOMA. NAME OF ORGANIZATION OR GOVERNMENT: RUSH UNIVERSITY MEDICAL CENTER (H) PURPOSE OF GRANT OR ASSISTANCE: NATIONAL GLAUCOMA RESEARCH BY DR. SHUNBIN XU ENTITLED: (G2011036) MICRORNAS IN GLAUCOMATOUS NEURODEGENERATION. INVESTIGATOR'S SUMMARY: THERE ARE RECENTLY DISCOVERED GENE-EXPRESSION CONTROLLERS-CALLED MICRORNAS-THAT PLAY IMPORTANT ROLES IN BOTH HEALTH AND DISEASE. HOWEVER, THE ROLES THAT MICRORNAS PLAY IN GLAUCOMA ARE COMPLETELY UNKNOWN. DR. SHUNBIN XU AND COLLEAGUES PLAN TO USE MICE THAT HAVE HUMAN-LIKE GLAUCOMA TO GATHER MICRORNAS FROM THE "OPTIC NERVE HEAD," A REGION OFTEN FIRST AFFECTED DURING GLAUCOMA DEVELOPMENT. BY COMPARING THE PRESENCE AND ACTIVITIES OF DIFFERENT MICRORNAS AT VARIOUS STAGES OF DISEASE IN THE OPTIC NERVE HEAD, THEY WILL DISCOVER THOSE THAT CHANGE IN CORRELATION WITH THE START AND PROGRESSION OF THE DISEASE. THESE MICRORNAS MAY BE USED AS NEW DRUG TARGETS FOR THE PREVENTION AND TREATMENT OF GLAUCOMA. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF ILLINOIS AT CHICAGO (H) PURPOSE OF GRANT OR ASSISTANCE: NATIONAL GLAUCOMA RESEARCH BY PAUL A. KNEPPER ENTITLED: (G2011047) ACTIVATION OF INNATE IMMUNE TOLL-4 RECEPTOR IN POAG. INVESTIGATOR'S SUMMARY: THE GOAL OF OUR PROJECT IS TO DETERMINE THE PROFILE OF HYALURONIC ACID, HYALURONIDASE, AND HYALURONIDASE INHIBITORS IN AQUEOUS HUMOR OF POAG AND NORMAL PATIENT POPULATIONS. HUMAN AQUEOUS HUMOR WILL BE PROVIDED FROM BOTH GLAUCOMATOUS AND NON-GLARCOMATOUS PATIENTS. GEL ELECTROPHORESIS WILL ALSO BE USED TO DETERMINE THE PROFILE OF HYALRUONIC ACID AND ITS RELATIVE SIZES IN AQUEOUS. WE WILL USE WESTERN BLOTS AND ZYMOGRAMS TO DETECT THE PRECENSE OF HYALURONIDASE AND HYALURONIDASE INHIBITORS. WE HAVE IDENTIFIED A UNIFIED SIGNALING PATHWAY BASED ON ACTIVATION OF INNATE IMMUNE SYSTEM WHICH RESULTS IN AN INFLAMMATORY CASCADE RESULTING IN POAG. WE HAVE IDENTIFIED THAT CELL TRAUMA CAUSES LOW-MOLECULAR-WEIGHT HYALURONIC ACID TO START THE PATHWAY. PREVENTION OF DEGRADATION OF HIGH-MOLECULAR-WEIGHT HYALURONIC ACID BY POTENT HYALURONIDASE INHIBITOR COULD BE NOVEL THERAPY AND THE FIRST THERAPY DIRECTLY AIMED AT THE CAUSE OF POAG.
		NAME OF ORGANIZATION OR GOVERNMENT: VANDERBILT UNIVERSITY MEDICAL CENTER (H) PURPOSE OF GRANT OR ASSISTANCE: NATIONAL GLAUCOMA RESEARCH BY DR. DAVID JOHN CALKINS ENTITLED: (G2011052) MAPPING THE PROTEIN AND LIPID SIGNATURE OF GLAUCOMA. INVESTIGATOR'S SUMMARY: AGING AND ELEVATED EYE PRESSURE BOTH CONTRIBUTE TO VISION LOSS IN GLAUCOMA BY CHANGING THE ACTIVITY OF PROTEINS AND FATS IN THE EYE. DRS. DAVID JOHN CALKINS, KEVIN SCHEY, AND COLLABORATORS HAVE PREVIOUSLY DEVELOPED AN INDUCIBLE GLAUCOMA MOUSE MODEL THAT WAS FUNDED IN PART THROUGH A PREVIOUS AHAF GRANT. IN THIS MODEL, TINY STYROFOAM BEADS ARE INJECTED INTO MOUSE EYES TO BLOCK THE FLOW OF A LIQUID CALLED THE AQUEOUS HUMOR, CAUSING AN INCREASE IN EYE PRESSURE THAT THEN DAMAGES THE OPTIC NERVE AND LEADS TO GLAUCOMA. THE RESEARCHERS WILL USE A SPECIAL KIND OF DETECTION LASER AND CAMERA (CALLED MALDI MASS SPECTROMETRY IMAGING) TO CREATE A "ROAD MAP" OF THE PROTEIN AND FAT CHANGES IN THE RETINA AND BRAIN. BY GIVING THESE MICE GLAUCOMA AT VARIOUS AGES, THIS APPROACH WILL SEPARATE AGE-DEPENDENT FROM EYE-PRESSURE-DEPENDENT CHANGES. THE RESULTS WILL GIVE CLUES FOR FUTURE TREATMENTS FOR GLAUCOMA AND PERHAPS FOR OTHER EYE OR BRAIN DISEASES ASSOCIATED WITH AGING, LIKE ALZHEIMER'S DISEASE OR MACULAR DEGENERATION. HUMAN AQUEOUS HUMOR WILL BE PROVIDED FROM BOTH GLAUCOMATOUS AND NON-GLARCOMATOUS PATIENTS. GEL ELECTROPHORESIS WILL ALSO BE USED TO DETERMINE THE PROFILE OF HYALRUONIC ACID AND ITS RELATIVE SIZES IN AQUEOUS. WE WILL USE WESTERN BLOTS AND ZYMOGRAMS TO DETECT THE PRECENSE OF HYALURONIDASE AND HYALURONIDASE INHIBITORS. NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. THOMAS A. FERGUSON ENTITLED: (M2011014) THE ROLE OF AUTOPHAGY IN AGE-RELATED EYE DISEASE. INVESTIGATOR'S SUMMARY: RETINAL PIGMENT EPITHELIAL (RPE) CELLS RECYCLE WASTE AND DELIVER NUTRIENTS TO THE LIGHT-DETECTING CELLS IN THE RETINA. EXCESSIVE BUILD-UP OF WASTE PRODUCTS, CALLED DRUSEN, HAPPENS AT THE BEGINNING OF DRY AGE-RELATED MACULAR DEGENERATION (AMD). DR. THOMAS FERGUSON AND COLLEAGUES WILL BE INVESTIGATING WHETHER MICE THAT HAVE BEEN MADE TO HAVE A FAULTY WASTE RECYCLING PROCESS-CALLED AUTOPHAGY-DEVELOP THE EYE DISEASE AMD. EYES THAT CAN'T RECYCLE ARE LIKELY TO SHOW SIGNS OF AGING, SENSITIVITY TO LIGHT AND DEVELOP BLINDNESS AT AN EARLY AGE AS A RESULT OF THE LOSS OF THIS RECYCLING. THESE RESEARCHERS HAVE ALREADY MADE MICE WITH PROBLEMS IN RPE AUTOPHAGY TO ADDRESS THEIR QUESTIONS. THEY WILL TRACK DOWN THE AMOUNT OF RECYCLING NEEDED TO KEEP EYES HEALTHY AND WHAT PROTEIN OR CHEMICAL "CULPRITS" TIP THE BALANCE TO INCREASE THE RISK OF GETTING AMD. IF A SUITABLE TARGET IN THE AUTOPHAGY PROCESS IS FOUND, THEY WILL DEVELOP A NEW THERAPY TO TREAT AMD. WE HAVE IDENTIFIED A UNIFIED SIGNALING PATHWAY BASED ON ACTIVATION OF INNATE IMMUNE SYSTEM WHICH RESULTS IN AN INFLAMMATORY CASCADE RESULTING IN POAG. WE HAVE IDENTIFIED THAT CELL TRAUMA CAUSES LOW-MOLECULAR-WEIGHT HYALURONIC ACID TO START THE PATHWAY. PREVENTION OF DEGRADATION OF HIGH-MOLECULAR-WEIGHT HYALURONIC ACID BY POTENT HYALURONIDASE INHIBITOR COULD BE NOVEL THERAPY AND THE FIRST THERAPY DIRECTLY AIMED AT THE CAUSE OF POAG. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF FLORIDA (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. MICHAEL E. BOULTON ENTITLED: (M2011017) PREPROGRAMMED BONE MARROW CELLS AS A SYSTEMIC THERAPY FOR DRY AMD. INVESTIGATOR'S SUMMARY: DRY AGE-RELATED MACULAR DEGENERATION (AMD) REPRESENTS 80 TO 90 PERCENT OF THE POPULATION CURRENTLY DIAGNOSED WITH AMD, YET THERE IS NO EFFECTIVE DISEASE-MODIFYING TREATMENT. RETINAL PIGMENTED EPITHELIAL (RPE) CELLS- IMPORTANT FOR WASTE RECYCLING AND DELIVERY OF NUTRIENTS TO THE LIGHT-DETECTING CELLS-ARE MYSTERIOUSLY KILLED-OFF IN DRY AMD. THEREFORE, THERE IS MUCH PROMISE IN REPLACING THE DAMAGED RPE CELLS WITH HEALTHY ONES. IN PREVIOUS STUDIES, DRS. MICHAEL BOULTON, MARIA GRANT AND COLLEAGUES MADE THE EXCITING DISCOVERY THAT CHANGING THE EXPRESSION OF ONE GENE IN ISOLATED BONE MARROW-DERIVED PLASMA CELLS (BMPCS)-A TYPE OF ADULT STEM CELL- TRANSFORMS THEM INTO RPE-LIKE CELLS. WHEN THESE CELLS ARE INJECTED BACK INTO THE BLOOD OF MICE WITH PHYSICALLY DAMAGED EYES, THEY GO TO THE RETINA, RENEW THE SINGLE-LAYER OF RPE CELLS, AND RE-ESTABLISH NORMAL VISION. DRS. BOULTON AND GRANT PLAN TO TEST THIS RPE-REPLACEMENT TREATMENT IN MICE WITH AMD. IF THIS TREATMENT IS PROVEN TO BE EFFECTIVE IN THESE MICE, IT COULD LEAD TO HUMAN CLINICAL TRIALS AND TREATMENT POSSIBILITIES WITHOUT THE NEED FOR INVASIVE EYE SURGERY OR INJECTIONS.
		NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF IOWA (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. VINIT B. MAHAJAN ENTITLED: (M2011021) CYTOKINE SIGNALING IN THE FOVEAL CHOROID IN AMD. INVESTIGATOR'S SUMMARY: IN NEOVASCULAR STAGES OF AGE-RELATED MACULAR DEGENERATION (WET AMD), LEAKY BLOOD VESSELS GROW INTO THE RETINA AND DAMAGE VISION. THESE BLOOD VESSELS ARE COAXED INTO THE RETINA BY A COMMUNICATION "CROSS-TALK" THAT MAY EXIST BETWEEN HUNDREDS OF PROTEINS AND CHEMICALS. DRS. VINIT MAHAJAN, JESSICA SKEIE AND COLLABORATORS WILL USE SPECIAL METHODS TO IDENTIFY THESE PROTEINS AND CHEMICALS FROM RETINA BLOOD VESSELS THAT WERE SURGICALLY REMOVED FROM THE EYES OF HUMAN DONORS WHO WERE EITHER HEALTHY OR WHO HAD BEEN DIAGNOSED WITH AMD. COMPARISON OF THE PROFILE BETWEEN HEALTHY AND DISEASED EYES SHOULD PRESENT A NUMBER OF CROSS-TALK CANDIDATES. THE IDENTITIES OF THESE CANDIDATES MAY THEN INSPIRE THE DESIGN OF COMBINATION DRUGS TO TREAT AMD BEFORE THE INVASION OF LEAKY BLOOD VESSELS PROMOTES RAPID LOSS OF VISION. THE METHODS WE WILL EMPLOY FOCUS ON ISOLATING A TARGET FOR POTENTIAL TREATMENT OF THE DISEASE POSSIBLY LINKED TO HYALURONIDASE INHIBITORS. THIS WOULD BE THE FIRST TIME THE UNDERLYING CAUSES OF POAG WOULD BE DIRECTLY TREAT AN UNDERLYING MECHANISM/CAUSE RATHER THAN MANAGING THE SYMPTOMS OF THE DISEASE. NAME OF ORGANIZATION OR GOVERNMENT: VANDERBILT UNIVERSITY MEDICAL CENTER (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. JONATHAN L. HAINES ENTITLED: (M2011046) THE GENETICS OF AMD IN AFRICAN-AMERICANS. INVESTIGATOR'S SUMMARY: MANY OF THE RISK GENES FOR AGE-RELATED MACULAR DEGENERATION (AMD) WERE DISCOVERED BY LOOKING AT DNA SAMPLES FROM CAUCASIAN (WHITE WITH EUROPEAN ANCESTRY) SUBJECTS. DRS. JONATHAN HAINES, ANITA AGARWAL, AND COLLABORATORS WILL LOOK FOR NEW RISK GENES BY COMPARING THE "SPELLING" OF THE DNA OF AFRICAN-AMERICANS WITH AMD TO THE DNA FROM UNRELATED AFRICAN-AMERICANS WITHOUT AMD. IF THIS GROUP DISCOVERS NEW RISK GENES, THEN IT MAY IMPLY THAT AMD STARTS AND/OR PROGRESSES IN AFRICAN-AMERICANS IN A DIFFERENT WAY THAN IT DOES FOR OTHER ETHNICITIES. HOWEVER, THE IDENTITY OF THE GENES FROM THIS STUDY MAY GIVE IDEAS FOR NEW TYPES OF PREVENTIONS AND TREATMENTS FOR EVERYONE DIAGNOSED WITH AMD. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PENNSYLVANIA (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. WENCHAO SONG ENTITLED: (M2011051) COMPLEMENT ACTIVATION IN RPE FUNCTION AND AMD PATHOGENESIS. INVESTIGATOR'S SUMMARY: THERE IS NO EFFECTIVE TREATMENT AVAILABLE FOR THE EARLY OR DRY TYPE OF AGE-RELATED MACULAR DEGENERATION (AMD). ONE IDEA FOR FUTURE TREATMENTS SPRUNG FROM THE DISCOVERY THAT A GROUP OF BLOOD PROTEINS THAT HELPS THE BODY TO ATTACK "FOREIGN INVADERS", CALLED THE COMPLEMENT SYSTEM, MAY INITIATE DRY AMD. DRS. WENCHAO SONG, IMRAN MOHAMMED, AND COLLABORATORS WILL CREATE MICE THAT HAVE HAD THE GENETIC "BRAKE" REMOVED FROM THE COMPLEMENT SYSTEM. THEY SUSPECT THAT THIS WILL CAUSE SEVERE INFLAMMATION AND DAMAGE THE RETINA IN A WAY THAT WILL RESEMBLE DRY AMD. IF THIS IS THE CASE, THEN THESE MICE COULD THEN BE USED AS A MODEL FOR TESTING NEW PREVENTIONS AND TREATMENTS FOR DRY AMD.
		NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF NOTRE DAME (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. DAVID RUSSELL HYDE ENTITLED: (M2011053) GENERATING A ZEBRAFISH MODEL TO STUDY AMD. INVESTIGATOR'S SUMMARY: IN AGE-RELATED MACULAR DEGENERATION (AMD), THE RETINAL PIGMENT EPITHELIUM (RPE) CELLS, WHICH ARE LOCATED BEHIND THE RETINA AND ARE ESSENTIAL TO KEEP THE LIGHT-DETECTING ROD AND CONE PHOTORECEPTOR CELLS ALIVE, ARE DAMAGED AND DIE. HOWEVER, IT IS UNCLEAR IF THE RPE CELL DEATH IS THE PRIMARY CAUSE OF AMD OR A SECONDARY EFFECT. TO ADDRESS THIS QUESTION, DR. DAVID HYDE AND COLLABORATORS WILL GENERATE A ZEBRAFISH MODEL OF AMD, WHERE A NUMBER OF THE RETINAL RPE CELLS DIE. THEY WILL THEN TEST WHETHER THE DEATH OF RPE CELLS IS SUFFICIENT TO CAUSE TWO HALLMARKS OF ADVANCED AMD-THE DEATH OF THE ADJACENT PHOTORECEPTOR CELLS AND THE APPEARANCE OF TEARS IN THE BLOOD-RETINA BARRIER (CALLED BRUCH'S MEMBRANE). SINCE ZEBRAFISH HAVE A NATURAL ABILITY TO REGENERATE A NUMBER OF BODY PARTS, INCLUDING RETINAL NEURONS, THESE RESEARCHERS WILL ALSO DETERMINE IF THE RPE CELL LAYER CAN SPONTANEOUSLY REPAIR ITSELF AND, IF SO, DETERMINE THE ORIGIN OF THESE NEW RPE CELLS. STUDYING HOW THE ZEBRAFISH EYE CAN REPAIR ITS RPE AND RETINA WILL GIVE CLUES FOR FUTURE RPE CELL REPLACEMENT THERAPIES FOR PEOPLE WITH AMD. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. MONTE JOEL RADEKE ENTITLED: (M2011064) THE EPIGENETICS OF RPE AGING. INVESTIGATOR'S SUMMARY: CHANGES IN RETINAL PIGMENT EPITHELIUM (RPE) CELLS DUE TO AGE AND ENVIRONMENTAL STRESS MAY BE ASSOCIATED WITH THE ONSET AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION (AMD). THESE PRESSURES CAN CAUSE CHANGES IN GENE ACTIVITY AND CELL HEALTH THROUGH A PROCESS CALLED EPIGENETICS. THIS PROCESS, WHERE GENES ARE EITHER ACTIVATED OR INACTIVATED BY THE ADDITION OF SPECIALIZED CHEMICAL GROUPS TO THE DNA, OCCURS NATURALLY DURING DEVELOPMENT AND PLAYS A KEY ROLE IN THE DETERMINATION OF CELLULAR FUNCTION. DR. MONTE RADEKE AND COLLABORATORS WILL DETERMINE IF CHANGES TO THE ORIGINAL EPIGENETIC PROGRAMMING OF RPE CAN HELP EXPLAIN THE DAMAGE OBSERVED IN AMD. THEY WILL USE A STATE-OF-THE-ART GLOBAL ANALYTICAL METHOD TO IDENTIFY GENES IN BOTH CULTURED RPE CELLS AND HUMAN DONOR RPE WHOSE EPIGENETIC PROGRAMMING BECOMES ALTERED WITH INCREASING AGE. IF AGING DOES CAUSE EPIGENETIC CHANGES TO GENES IN RPE CELLS, THIS RESEARCH COULD LEAD TO NEW TREATMENTS FOR AMD. NAME OF ORGANIZATION OR GOVERNMENT: THE SCHEPENS EYE RESEARCH INSTITUTE (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. BRUCE RICHARD KSANDER ENTITLED: (M2011069) NALP3 ACTIVATION TRIGGERS DEVELOPMENT OF AMD. INVESTIGATOR'S SUMMARY: RETINAL PIGMENT EPITHELIAL (RPE) CELLS SUPPORT THE LIGHT-DETECTING PHOTORECEPTOR CELLS BY RECYCLING AND REMOVING WASTE PRODUCTS. IF RPE CELLS ARE UNHEALTHY, THEN THIS WASTE CAN BUILD-UP AND DAMAGE THE RETINA. INFLAMMATION IS AN IMPORTANT PART OF THE AMD DISEASE PROCESS, AND RPE CELLS HAVE THEIR OWN SPECIAL TYPE OF PROTEINS-CALLED THE "INFLAMMASOME"-TO MONITOR AND DETERMINE IF THE RPE ARE WORKING PROPERLY. IN FACT, IF THIS RPE WASTE RECYCLING AND REMOVAL PROCESS ISN'T FUNCTIONING PROPERLY, THE INFLAMMASOME SENDS OUT SIGNALS FOR THE IMMUNE SYSTEM TO SWOOP IN AND KILL THE MALFUNCTIONING RPE CELLS. DR. KSANDER AND COLLABORATORS HAVE DISCOVERED A NEW RISK GENE-CALLED NALP3-THAT IS EXPRESSED IN RETINAL CELLS AND IS SUSPECTED TO BE IMPORTANT IN TRIGGERING AMD VIA THE INFLAMMASOME. THESE RESEARCHERS WILL DETERMINE WHETHER THIS GENE IS INVOLVED IN THE DEATH OF RPE CELLS AND, IF SO, WHETHER IT WILL BE A NEW TARGET FOR TREATMENT OF AMD.
		NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. DONALD J. ZACK ENTITLED: (M2011077) HIGH CONTENT SCREEN FOR RPE CELL PROTECTIVE COMPOUNDS. INVESTIGATOR'S SUMMARY: RETINAL PIGMENT EPITHELIAL (RPE) CELLS ARE ESSENTIAL FOR NORMAL RETINAL FUNCTION, BEING RESPONSIBLE FOR MAINTAINING THE DELICATE BALANCE BETWEEN WASTE REMOVAL AND NUTRIENT DELIVERY THAT IS NECESSARY TO SUSTAIN THE HEALTH AND FUNCTION OF PHOTORECEPTORS. DYSFUNCTION AND DEATH OF RPE CELLS PLAYS AN IMPORTANT ROLE IN THE ETIOLOGY OF AGE-RELATED MACULAR DEGENERATION (AMD). THERE ARE NO KNOWN DRUGS THAT EFFECTIVELY PREVENT THIS AMD-ASSOCIATED RPE DYSFUNCTION AND CELL DEATH. DRS. DONALD ZACK, CINDY BERLINICKE, AND COLLEAGUES PROPOSE TO IDENTIFY SMALL MOLECULES, POTENTIAL DRUGS THAT CAN PROMOTE THE HEALTH AND SURVIVAL OF RPE CELLS. THESE RESEARCHERS WILL LOOK FOR THESE PROTECTIVE SMALL MOLECULE DRUGS BY SCREENING THOUSANDS OF CANDIDATES WITH AN AUTOMATED, ROBOTIC MICROSCOPE SYSTEM. THE IDENTITY OF EFFECTIVE CANDIDATES COULD GIVE CLUES TO UNDERSTANDING WHAT CAUSES AMD AND ALSO COULD PROVIDE CANDIDATE MOLECULES THAT COULD BE DEVELOPED INTO NOVEL DRUG TREATMENTS FOR AMD. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE (H) PURPOSE OF GRANT OR ASSISTANCE: MACULAR DEGENERATION RESEARCH BY DR. MARGARET A PERICAK-VANCE ENTITLED: (M2011078) WHOLE EXOME SEQUENCING IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THERE ARE MANY GENES THAT ARE LINKED TO THE RISK OF DEVELOPING AGE-RELATED MACULAR DEGENERATION (AMD), BUT THERE IS STILL ROOM TO DISCOVER MORE. IN THIS PROPOSED PROJECT, DRS. MARGARET PERICAK-VANCE, WILLIAM SCOTT, AND COLLEAGUES WILL STUDY THE DNA OF TWO GROUPS OF PEOPLE THAT SHOULD INCREASE THEIR CHANCES OF FINDING NEW RISK GENES. ONE GROUP HAS ADVANCED AMD DESPITE NOT HAVING ANY OF THE KNOWN RISK VARIANTS IN THE GENES ASSOCIATED WITH AMD RISK (INCLUDING CFH AND ARMS2) AND THE OTHER GROUP DOESN'T HAVE AMD DESPITE HAVING KNOWN RISK VARIANTS IN THESE GENES. THESE RESEARCHERS WILL USE NEW GENE READING TECHNIQUES TO LOOK AT THE "WHOLE EXOME" OR THE DNA SPELLING OF THE MOST-USED BOOKS IN A PERSON'S GENETIC LIBRARY. CATALOGUING THE GENE CHANGES IN BOTH SETS OF PEOPLE WITH AMD WILL LEAD TO BETTER UNDERSTANDING OF HOW THIS DISEASE STARTS AND GIVE CLUES TO FUTURE PREVENTIONS AND TREATMENTS.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990 or 990-EZ) 2010

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" to Form 990, Part IV, line 33, 34, 35, 36, or 37.
MediumBullet

Attach to Form 990. MediumBullet

See separate instructions.

OMB No. 1545-0047

2010

Open to Public Inspection

Name of the organization

AMERICAN HEALTH ASSISTANCE FOUNDATION

Employer identification number

23-7337229

Part I

Identification of Disregarded Entities (Complete if the organization answered "Yes" on Form 990, Part IV, line 33.)

(a) Name, address, and EIN of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
(1) NATIONAL DEVELOPMENT LLC 22512 GATEWAY CENTER DRIVE CLARKSBURG,MD20871 23-7337229	PROPERTY RENTAL AND MANAGMENT	MD	561,553	5,766,778	N/A
(2) AMERICAN HEALTH ASSISTANCE LLC 22512 GATEWAY CENTER DRIVE CLARKSBURG,MD20871 23-7337229	OWNER OF AHAF HEADQUARTERS	MD		4,742,285	N/A

Part II

Identification of Related Tax-Exempt Organizations (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled organization
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No

For Privacy Act and Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2010

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a partnership during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust (Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership

Schedule R (Form 990) 2010

Page 3

Part V

Transactions With Related Organizations (Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35, 35A, or 36.)

Note. Complete line 1 if any entity is listed in Parts II, III or IV.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest (ii) annuities (iii) royalties (iv) rent from a controlled entity . . . . . . . . . . . . . . . . . . . . . . .

b Gift, grant, or capital contribution to other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

c Gift, grant, or capital contribution from other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

d Loans or loan guarantees to or for other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

e Loans or loan guarantees by other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

f Sale of assets to other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

g Purchase of assets from other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

h Exchange of assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

i Lease of facilities, equipment, or other assets to other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

j Lease of facilities, equipment, or other assets from other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . .

k Performance of services or membership or fundraising solicitations for other organization(s) . . . . . . . . . . . . . . . . . . . . . .

l Performance of services or membership or fundraising solicitations by other organization(s) . . . . . . . . . . . . . . . . . . . . . .

m Sharing of facilities, equipment, mailing lists, or other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

n Sharing of paid employees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

o Reimbursement paid to other organization for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

p Reimbursement paid by other organization for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

q Other transfer of cash or property to other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

r Other transfer of cash or property from other organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of other organization	(b) Transaction type(a-r)	(c) Amount involved	(d) Method of determining amount involved
(1)
(2)
(3)
(4)
(5)
(6)

Schedule R (Form 990) 2010

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership (Complete if the organization answered "Yes" on Form 990, Part IV, line 37.)

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Are all partners section 501(c)(3) organizations?		(e) Share of end-of-year assets	(f) Disproprtionate allocations?		(g) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	(h) General or managing partner?
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(e) Share of end-of-year assets	Yes	No	(g) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Schedule R (Form 990) 2010

Page 5

Part VII

Supplemental Information

Complete this part to provide additional information for responses to questions on Schedule R (see instructions).

Identifier	Return Reference	Explanation

Additional Data

Software ID:
Software Version:

1	Briefly describe the organization’s mission or most significant activities: SEEKS TO ERADICATE AGE-RELATED AND DEGENERATIVE DISEASES.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ....	3	9
4	Number of independent voting members of the governing body (Part VI, line 1b) ....	4	9
5	Total number of individuals employed in calendar year 2010 (Part V, line 2a) ...	5	49
6	Total number of volunteers (estimate if necessary) ....	6	163
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ..	7a	0
b	Net unrelated business taxable income from Form 990-T, line 34 ..	7b	0

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	21,879,337	18,261,062
9	Program service revenue (Part VIII, line 2g) .........	0	0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	806,428	2,575,465
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	664,334	706,437
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)...................	23,350,099	21,542,964
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	8,022,940	5,594,209
14	Benefits paid to or for members (Part IX, column (A), line 4) ....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	2,846,514	3,157,144
16a	Professional fundraising fees (Part IX, column (A), line 11e)....	415,036	476,168
b	Total fundraising expenses (Part IX, column (D), line 25) 5,017,575
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24f)....	11,862,569	11,872,123
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	23,147,059	21,099,644
19	Revenue less expenses. Subtract line 18 from line 12......	203,040	443,320
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16)............	39,813,376	37,750,130
21	Total liabilities (Part X, line 26)............	16,651,163	15,113,621
22	Net assets or fund balances. Subtract line 21 from line 20 .....	23,162,213	22,636,509

Sign Here

	Signature of officer	Date

	Type or print name and title.

Paid Preparer's Use Only	Preparer's signature	Date	Check if self- employed	Preparer’s taxpayer identification number (see instructions)
	Firm’s name (or yours if self-employed), address, and ZIP + 4			EIN
				Phone no.


4a	(Code: ) (Expenses $ 9,354,750 including grants of $ 3,399,812 ) (Revenue $ )
	ALZHEIMER'S DISEASE RESEARCH (ADR) - ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE. ADR AWARDS FALL INTO THREE CATEGORIES. STANDARD AND PILOT AWARDS ARE INTENDED FOR ESTABLISHED RESEARCHERS, AND POSTDOCTORAL RESEARCH FELLOWSHIPS SUPPORT SCIENTISTS WHO ARE TRAINING TO ASSUME THE RESPONSIBILITIES OF DIRECTING THEIR FIRST RESEARCH LABORATORY. DURING THE FISCAL YEAR ENDED MARCH 31, 2011, 17 NEW ADR PROJECTS WERE OFFERED TOTALING $3,399,812. THE PROJECTS RANGE FROM ADVANCED GENETIC STUDIES THAT AIM TO IDENTIFY INHERITABLE RISKS FOR ALZHEIMER'S DISEASE THROUGH THOSE DESIGNED TO CREATE NEW THERAPEUTIC INTERVENTIONS AGAINST THE DISEASE. ADDITIONAL INFORMATION ABOUT SPECIFIC PROJECTS IS DETAILED IN SCHEDULES F & I. IN THE PRECEDING YEAR, AHAF PARTNERED WITH THE ACADEMIC JOURNAL "MOLECULAR NEURODEGENERATION" TO DEVELOP THE PUBLICATION AS THE OFFICIAL JOURNAL OF THE AMERICAN HEALTH ASSISTANCE FOUNDATION. IT PUBLISHES TECHNICAL PAPERS PRIMARILY ON TOPICS RELATED TO THE ADR PROGRAM. AS AN "OPEN ACCESS" JOURNAL, THERE IS NO FEE FOR READERS, AND ALL CONTENT IS FREELY AVAILABLE THROUGH ITS WEBSITE.IN NOVEMBER 2010, ADR ONCE AGAIN PARTNERED WITH EUROPEAN AFFILIATE ORGANIZATION ISAO TO HOST A THREE-DAY INTENSIVE SEMINAR FOR EARLY-CAREER SCIENTISTS. THIS EVENT FEATURED HIGH LEVEL INTERACTIONS WITH WELL ESTABLISHED ALZHEIMER'S DISEASE RESEARCH LEADERS, WHO LECTURED AND MODERATED SMALL-GROUP DISCUSSIONS. ADR PROVIDES INFORMATION ABOUT RISK FACTORS, PREVENTATIVE MEASURES, DIAGNOSIS, TREATMENT, AND LIFESTYLE CHANGES FOR ALZHEIMER'S PATIENTS, THEIR FAMILIES, CAREGIVERS, THE PUBLIC, TARGETED GROUPS, AND THE MEDIA. THE PROGRAM ALSO ENSURES THAT THE PUBLIC AND MEDIA ARE AWARE OF AHAF-DONOR-FUNDED ALZHEIMER'S DISEASE RESEARCH AND THE LATEST SCIENTIFIC DEVELOPMENTS. ADR PROVIDES THIS INFORMATION THROUGH EALERTS, NEWSLETTERS, SOCIAL MEDIA, INFORMATIONAL PUBLICATIONS, AND TV AND RADIO PUBLIC SERVICE ANNOUNCEMENTS (PSAS). MEDICAL AND RESEARCH NEWS UPDATES ARE ROUTINELY POSTED ON THE AHAF WEBSITE AND DISSEMINATED THROUGH PRINT AND OTHER ELECTRONIC MEDIA.AHAF PROVIDES A NUMBER OF PATIENT EDUCATION MATERIALS IN PRINT AND PDF FORMATS. MOST POPULAR AMONG THESE PUBLICATIONS IS "LIVING WITH ALZHEIMER'S DISEASE," A 34-PAGE BOOKLET WITH INFORMATION INCLUDING RISK FACTORS AND MITIGATION, CAUSES AND TREATMENT OF THE DISEASE, COPING AND CAREGIVING STRATEGIES, FINANCIAL AND LEGAL PLANNING, AND RESOURCES FOR PATIENTS AND FAMILIES. OTHER MATERIALS INCLUDE:1. "UNDERSTANDING ALZHEIMER'S: IT'S NOT JUST FORGETFULNESS," 2. "CARE FOR THE CAREGIVER: MANAGING STRESS,"3. "SAFETY AND THE OLDER DRIVER,"4. "STAYING SAFE: WANDERING AND THE ALZHEIMER'S PATIENT." ADR PUBLICATIONS ARE AVAILABLE IN ENGLISH AND HAVE ALSO BEEN TRANSLATED BY NATIVE SPEAKERS FOR SPANISH AUDIENCES. ALL VERSIONS ARE ALL AVAILABLE IN PDF ON THE AHAF WEBSITE. AN ADR PSA, "UNDERSTANDING THIS DEBILITATING DISEASE," WAS PRODUCED IN ENGLISH AND SPANISH THIS FISCAL YEAR AND RAN NATIONWIDE ON TV AND RADIO. ADR EARNED $12,374,011 IN DONATED MEDIA SERVICES. DURING THE FOURTH QUARTER, AHAF SCIENTIFIC AFFAIRS STAFF PRESENTED ON ALZHEIMER'S DISEASE TO COMMUNITY ORGANIZATIONS IN MARYLAND. THE ADR NEWSLETTER WAS SENT TO THOUSANDS OF CONSTITUENTS TWICE THIS YEAR, AND INFORMATION ABOUT ALZHEIMER'S DISEASE WAS INCLUDED IN THREE EDITIONS OF THE AHAF INSIDER REPORT. THREE EDITIONS OF THE AHAF ENEWSLETTER, WHICH FOCUSES ON FIGHTING AGE-RELATED DISEASE AND INCLUDES INFORMATION ABOUT ALZHEIMER'S DISEASE, WERE DISTRIBUTED TO TENS OF THOUSANDS OF INTERESTED READERS. MORE THAN 244 ANSWERS TO ASK AN EXPERT QUESTIONS WERE PROVIDED DURING THE YEAR. THIS QUESTION-AND-ANSWER FORUM PROVIDES PROFESSIONALLY RESEARCHED ANSWERS TO QUESTIONS SUBMITTED TO AHAF. NEARLY 30 EALERTS ON ALZHEIMER'S DISEASE WERE SENT TO MEMBERS OF ADR'S OPT-IN DISTRIBUTION LIST. SEVERAL MESSAGES ON ALZHEIMER'S DISEASE WERE DISTRIBUTED WEEKLY THROUGHOUT THE YEAR ON AHAF'S SOCIAL MEDIA CHANNELS, ENGAGING THOUSANDS OF FOLLOWERS. ADR MAILED AWARENESS-RAISING MATERIALS ON ALZHEIMER'S DISEASE TO HUNDREDS OF THOUSANDS OF HOUSEHOLDS, WITH MESSAGES FOCUSING ON: 1. SYMPTOM RECOGNITION AND STEPS THE PUBLIC SHOULD TAKE, SUCH AS MAKING AN APPOINTMENT WITH THE DOCTOR IF ANY OF THESE SYMPTOMS EXIST.2. LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE; I.E. EXERCISE YOUR MIND BY PLAYING BOARD GAMES, CARDS, AND PUZZLES.3. RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS ALZHEIMER'S DISEASE.

4b	(Code: ) (Expenses $ 2,983,739 including grants of $ 1,194,397 ) (Revenue $ )
	MACULAR DEGENERATION RESEARCH (MDR) - THROUGH AN OUTREACH EFFORT IN KEY TRADE PUBLICATIONS AND INFORMATION DISTRIBUTION AT MAJOR CONFERENCES FOR EYE RESEARCHERS, MDR ENCOURAGES JUNIOR- AND SENIOR-LEVEL SCIENTISTS AROUND THE WORLD TO APPLY FOR ITS PRESTIGIOUS MACULAR DEGENERATION RESEARCH GRANT PROGRAM. MDR ANNUALLY OFFERS GRANTS TO SCIENTISTS THROUGH A SOPHISTICATED PEER-REVIEW PROCESS MANAGED BY THE MDR SCIENTIFIC REVIEW COMMITTEE. THIS GROUP OF THE FIELD'S LEADING SCIENTISTS BASE THESE DECISIONS ON SCIENTIFIC MERIT USING A SOPHISTICATED EVALUATION SYSTEM. DURING THE FISCAL YEAR ENDING MARCH 31, 2011, MDR AWARDED $1,194,397 IN GRANTS TO 12 RESEARCHERS. THE PROJECTS RANGE FROM STUDIES TO UNDERSTAND THE INFLUENCE OF RACIAL IDENTITY ON INCREASED RISK FOR MACULAR DEGENERATION TO THOSE AIMED AT DESIGNING NEW CELL-BASED THERAPIES TO TARGET AND ELIMINATES THE MOLECULAR CHANGES THAT LEAD TO MACULAR DEGENERATION. ADDITIONAL DETAILS ABOUT SPECIFIC PROJECTS ARE DETAILED IN SCHEDULES F & I. MDR DEVELOPED AND LAUNCHED THE CHILDREN'S CORNER FOR MACULAR DEGENERATION, A WEBSITE AIMED AT TEACHING CHILDREN ABOUT THE DEGENERATIVE DISEASE THROUGH STORIES, INTERACTIVE GAMES, AND SHARING ACTIVITIES. INFORMATION ABOUT THIS GREAT NEW RESOURCE WAS SHARED AMONG PUBLICS INTERESTED IN LOW VISION, INCLUDING TENS OF THOUSANDS OF OPTOMETRISTS AROUND THE COUNTRY. MDR PROACTIVELY DISSEMINATES INFORMATION TO THE PUBLIC DIRECTLY AND VIA THE MEDIA. THIS INCLUDES INFORMATION ON RISK FACTORS, PREVENTATIVE MEASURES, A DESCRIPTION OF AGE-RELATED MACULAR DEGENERATION, THE PROGRESSION OF THE DISEASE, AVAILABLE MEDICAL TREATMENTS, SUGGESTIONS FOR ADAPTING TO LOW VISION, AND NEW RESEARCH DEVELOPMENTS. MEDICAL AND RESEARCH NEWS UPDATES ON MACULAR DEGENERATION ARE ROUTINELY POSTED ON THE AHAF WEBSITE.MDR CONTINUED TO DISTRIBUTE HIGH QUALITY INFORMATIVE MATERIALS, INCLUDING "MACULAR DEGENERATION: THE ESSENTIAL FACTS," THE COMPREHENSIVE BOOKLET "LIVING WITH MACULAR DEGENERATION", "SAFETY AND THE OLDER DRIVER", AND THE "LOW VISION RESOURCE LIST". ALL MDR PUBLICATIONS ARE IN LARGE PRINT AND AVAILABLE IN PDF IN ENGLISH AND SPANISH ON THE AHAF WEBSITE. IN THIS PAST YEAR, THE WEBSITE WAS UPGRADED TO ENSURE ITS PRINTED PAGES ARE MORE READABLE. AN MDR PSA, "THERE IS HOPE THAT A CURE WILL BE FOUND" RAN NATIONWIDE IN ENGLISH AND SPANISH ON TV AND RADIO THIS FISCAL YEAR. MDR GENERATED $714,885 IN DONATED MEDIA SERVICES. ANOTHER PSA, FOCUSING ON THE CHILDREN'S CORNER FOR MACULAR DEGENERATION, WAS PRODUCED IN THIS FISCAL YEAR AND WILL AIR IN THE MONTHS AHEAD. TWO EDITIONS OF THE MDR NEWSLETTER WERE SENT TO INTERESTED CONSTITUENTS. THE AHAF INSIDER REPORT, WHICH INCLUDED INFORMATION ABOUT MACULAR DEGENERATION, WAS DISTRIBUTED THREE TIMES THIS YEAR. THREE EDITIONS OF THE AHAF ENEWSLETTER, WHICH FOCUSES ON FIGHTING AGE-RELATED DISEASE AND INCLUDES INFORMATION ABOUT MACULAR DEGENERATION, WERE DISTRIBUTED TO TENS OF THOUSANDS OF INTERESTED READERS. MORE THAN 200 ANSWERS TO ASK AN EXPERT QUESTIONS ON MACULAR DEGENERATION WERE PROVIDED VIA EMAIL AND ON THE AHAF WEBSITE DURING THE YEAR. NEARLY 20 EALERTS WERE SENT TO MEMBERS OF THE MACULAR DEGENERATION OPT-IN DISTRIBUTION LIST. EACH WEEK AHAF DISTRIBUTED A RANGE OF MESSAGES ON MACULAR DEGENERATION USING ITS SOCIAL MEDIA CHANNELS, ENGAGING THOUSANDS OF FOLLOWERS. MDR MAILED AWARENESS-RAISING MATERIALS ON MACULAR DEGENERATION TO TENS OF THOUSANDS OF HOUSEHOLDS, WITH HIGHLIGHTED MESSAGES INCLUDING: 1. IDENTIFYING SYMPTOMS AND RECOMMENDING STEPS THE PUBLIC CAN TAKE, SUCH AS GETTING COMPREHENSIVE EYE EXAMS REGULARLY.2. LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH AND REDUCE THE LIKELIHOOD OF DISEASE, LIKE EATING AN "EYE HEALTHY" DIET.3. CURRENT RESEARCH AND THE PREVENTATIVE MEASURES THAT CAN BE TAKEN TO HELP REDUCE THE RISK OF MACULAR DEGENERATION.

4c	(Code: ) (Expenses $ 1,474,514 including grants of $ 1,000,000 ) (Revenue $ )
	NATIONAL GLAUCOMA RESEARCH (NGR) - NGR GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT. DURING THE FISCAL YEAR ENDING MARCH 31, 2011, NGR AWARDED $1,000,000 IN GRANTS TO 10 RESEARCHERS. THE PROJECTS RANGE FROM EXAMINATIONS OF THE ROOTS OF GLAUCOMA IN THE BRAIN TO STUDIES DESIGNED TO ALLEVIATE THE BUILDUP OF PRESSURE WITHIN THE EYE, A DOCUMENTED RISK FACTOR FOR GLAUCOMA. ADDITIONAL DETAILS ABOUT SPECIFIC PROJECTS ARE DETAILED IN SCHEDULES F & I.THE NGR COMMUNICATIONS OUTREACH PROGRAM ENCOURAGES PEOPLE TO TAKE PREVENTATIVE MEASURES (E.G., SCHEDULING REGULAR EYE EXAMS) AND TO UNDERSTAND RISK FACTORS AND SYMPTOMS. IT ALSO PROVIDES INFORMATION ON TREATMENTS AND RESOURCES FOR ADJUSTING TO LOW VISION. IN ADDITION, REGULAR UPDATES ON CURRENT GLAUCOMA RESEARCH AND THE LATEST STUDY RESULTS ARE DISSEMINATED TO THE PUBLIC DIRECTLY AND THROUGH THE WEB AND THE MEDIA. AS A CURATOR OF CRITICAL NEWS IN THE FIELD, NGR DISTRIBUTED 11 EALERTS TO PEOPLE INTERESTED IN GLAUCOMA RESEARCH IN THIS FISCAL YEAR. NGR RESPONDED TO 180 ASK AN EXPERT QUESTIONS, SENDING EMAILS DIRECTLY TO THE INQUIRERS AND POSTING ANSWERS ON THE WEBSITE FOR ALL TO SEE. TWO NGR PUBLICATIONS- "ESSENTIAL FACTS ON GLAUCOMA" AND "LIVING WITH GLAUCOMA" -CONTINUE TO BE IN GREAT DEMAND. OTHER POPULAR PUBLICATIONS INCLUDE "SAFETY AND THE OLDER DRIVER" AND THE "LOW VISION RESOURCE LIST". ALL NGR PUBLICATIONS ARE IN LARGE PRINT AND AVAILABLE IN PDF IN ENGLISH AND SPANISH ON THE AHAF WEBSITE. THREE EDITIONS OF THE NGR NEWSLETTER WERE MAILED TO READERS DURING THE YEAR, AND INFORMATION ABOUT GLAUCOMA WAS INCLUDED IN TWO EDITIONS OF THE AHAF INSIDER REPORT. THESE PUBLICATIONS ARE AVAILABLE ON THE AHAF WEBSITE AS WELL. WITH ONE OF THE MOST ACTIVE SOCIAL MEDIA FOLLOWINGS IN THE GLAUCOMA FIELD, NGR COMMUNICATED NEWS AND INFORMATION SEVERAL TIMES EACH WEEK VIA THESE NETWORKING CHANNELS. AHAF DEVELOPED A PSA THIS FISCAL YEAR TITLED "YOU HAVE QUESTIONS; WE HAVE ANSWERS". PRODUCED IN ENGLISH AND SPANISH, VERSIONS WERE DISTRIBUTED AND AIRED NATIONWIDE ON TV, RADIO, AND THE INTERNET. NGR GENERATED $6,449,712 IN DONATED MEDIA SERVICES. IN ADDITION TO THESE PRODUCED SEGMENTS, NGR WROTE AND DISTRIBUTED RADIO SCRIPT PSAS IN JANUARY AND FEBRUARY OF 2011, WHICH RAN ON STATIONS AROUND THE COUNTRY. NGR CREATED A SERIES OF SEVEN VIDEOS DESCRIBING GLAUCOMA RISK FACTORS, SYMPTOMS, DIAGNOSIS, TREATMENTS, LIFESTYLE CHANGES, AND RESEARCH. THESE VIDEOS, PRODUCED WITH THE MONKEYSEE NETWORK, ARE AVAILABLE THROUGH DOZENS OF ONLINE OUTLETS AS WELL AS THE AHAF SITE AND YOUTUBE. NGR MAILED AWARENESS-RAISING MATERIALS ON GLAUCOMA TO TENS OF THOUSANDS OF HOUSEHOLDS, FOCUSING ON: 1. SYMPTOM RECOGNITION, URGING PEOPLE TO SCHEDULE AN EYE EXAMINATION IF ANY OF THESE SYMPTOMS EXIST.2. LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH AND STEPS THE PUBLIC CAN TAKE TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE; I.E. EAT AN "EYE HEALTHY" DIET.3. TREATMENTS AND MEDICINES TO CONTROL THE DISEASE AND ANY ACTIONS THAT CAN BE TAKEN TO ASSIST PEOPLE LIVING WITH GLAUCOMA AND THEIR FAMILIES.

4d	Other program services. (Describe in Schedule O.)
	(Expenses $ including grants of $ ) (Revenue $ )
4e	Total program service expenses$ 13,813,003

(A) Name and Title	(B) Average hours per week (describe hours for related organizations in Schedule O)	(C) Position (check all that apply)			(D) Reportable compensation from the organization (W- 2/1099-MISC)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
(A) Name and Title
(1) BRIAN K REGAN PHD CHAIRMAN	10.00	X	X		0	0	0
(2) JONATHAN RICE ESQ VICE CHAIRMAN	4.00	X	X		0	0	0
(3) NICHOLAS W RAYMOND TREASURER	12.00	X	X		0	0	0
(4) MICHAEL H BARNETT ESQ SECRETARY	3.00	X	X		0	0	0
(5) SCOTT RODGVILLE CPA ASSIST. TREASURER	3.00	X	X		0	0	0
(6) GRACE FRISONE ASSIST. SECRETARY	10.00	X	X		0	0	0
(7) DIANE MARCELLO DIRECTOR	3.00	X			0	0	0
(8) HENRY POWNALL PHD DIRECTOR	2.00	X			0	0	0
(9) HON GORDON STRAUSS DIRECTOR - UNTIL 4/10	1.00	X			0	0	0
(10) ELTJO R ED SCHOONVELD DIRECTOR	8.00	X			0	0	0
(11) STACY PAGOS HALLER PRESIDENT/CEO	55.00		X		245,304	0	29,869
(12) DONNA CALLISON VP, DEVELOPMENT	45.00			X	117,036	0	14,707
(13) GUY EAKIN PH D VP, SCIENTIFIC AFFAIRS	45.00			X	115,059	0	48,250
(14) DAVID F MARKS CPA CMA VP, FINANCE & ADMINISTRATION	45.00			X	141,144	0	42,305

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)............	618,543	0	135,131

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512, 513, or 514
1a	Federated campaigns..1a		17,779
b	Membership dues....1b
c	Fundraising events....1c		40,642
d	Related organizations...1d
e	Government grants (contributions)1e

f	All other contributions, gifts, grants, and similar amounts not included above1f		18,202,641
g	Noncash contributions included in lines 1a-1f:$ 25,820
h	Total. Add lines 1a-1f.......			18,261,062
			Business Code
2a
b
c
d
e
f	All other program service revenue .
g	Total. Add lines 2a–2f........
3	Investment income (including dividends, interest
	and other similar amounts).....			667,637			667,637
4	Income from investment of tax-exempt bond proceeds..
5	Royalties............			211,840			211,840
		(i) Real	(ii) Personal
6a	Gross Rents	563,762
b	Less: rental expenses	43,988
c	Rental income or (loss)	519,774
d	Net rental income or (loss).......			519,774			519,774
		(i) Securities	(ii) Other
7a	Gross amount from sales of assets other than inventory	33,751,756
b	Less: cost or other basis and sales expenses	31,843,928
c	Gain or (loss)	1,907,828
d	Net gain or (loss)..........			1,907,828			1,907,828
8a	Gross income from fundraising events (not including $ 40,642 of contributions reported on line 1c). See Part IV, line 18 ...
	a		13,580
b	Less: direct expenses ...b		38,771
c	Net income or (loss) from fundraising events..			-25,191			-25,191
9a	Gross income from gaming activities. See Part IV, line 19 ...
	a
b	Less: direct expenses ...b
c	Net income or (loss) from gaming activities...
10a	Gross sales of inventory, less returns and allowances .
	a
b	Less: cost of goods sold ..b
c	Net income or (loss) from sales of inventory..
Miscellaneous Revenue			Business Code
11a	OTHER REVENUE		900,099	14			14
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			14
12	Total revenue. See Instructions....			21,542,964	0	0	3,281,902


				(A) Beginning of year		(B) End of year
1	Cashnon-interest-bearing ..........			5,535,237	1	3,151,374
2	Savings and temporary cash investments .......			917,491	2	481,803
3	Pledges and grants receivable, net .........			3,382,454	3	2,575,645
4	Accounts receivable, net .........				4
5	Receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of
	Schedule L ..........				5
6	Receivables from other disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B). Complete Part II of
	Schedule L ..........				6
7	Notes and loans receivable, net .............			388,680	7	316,096
8	Inventories for sale or use ..............			203,848	8	134,231
9	Prepaid expenses and deferred charges ............			169,705	9	90,659
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	11,038,055
b	Less: accumulated depreciation. .....	10b	2,153,265	8,920,355	10c	8,884,790
11	Investments—publicly traded securities ..........			18,646,572	11	18,659,162
12	Investments—other securities. See Part IV, line 11 ......			775,876	12	2,580,114
13	Investments—program-related. See Part IV, line 11 ..				13
14	Intangible assets .........				14
15	Other assets. See Part IV, line 11 ...........			873,158	15	876,256
16	Total assets. Add lines 1 through 15 (must equal line 34)...			39,813,376	16	37,750,130
17	Accounts payable and accrued expenses .			965,669	17	1,003,163
18	Grants payable ..........			12,513,554	18	11,181,827
19	Deferred revenue ..........				19
20	Tax-exempt bond liabilities ..........			1,560,000	20	1,310,000
21	Escrow or custodial account liability. Complete Part IV of Schedule D..				21
22	Payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........				22
23	Secured mortgages and notes payable to unrelated third parties ..				23
24	Unsecured notes and loans payable to unrelated third parties ....				24
25	Other liabilities. Complete Part X of Schedule D.....			1,611,940	25	1,618,631
26	Total liabilities. Add lines 17 through 25.....			16,651,163	26	15,113,621
	Organizations that follow SFAS 117, check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets .....			9,173,838	27	10,772,583
28	Temporarily restricted net assets .....			13,898,375	28	11,773,926
29	Permanently restricted net assets .....			90,000	29	90,000
	Organizations that do not follow SFAS 117, check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds .....				30
31	Paid-in or capital surplus, or land, building or equipment fund .....				31
32	Retained earnings, endowment, accumulated income, or other funds				32
33	Total net assets or fund balances .....			23,162,213	33	22,636,509
34	Total liabilities and net assets/fund balances .....			39,813,376	34	37,750,130

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926 (see instructions for Form 926).................	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If " Yes," the organization may be required to file Form 3520 and/or Form 3520-A. (see instructions for Forms 3520 and 3520-A)..........	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with respect to Certain Foreign Corporations. (see instructions for Form 5471)..............................	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If "Yes," the organization may be required to file Form 8621, Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see instructions for Form 8621)	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with respect to Certain Foreign Partnerships. (see instructions for Form 8865)....................................	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to file Form 5713, International Boycott Report (see instructions for Form 5713)................................................	Yes	No